

U.S. Department of Justice
Federal Bureau of Investigation

Drug Deterrence Program

122631

U.S. Department of Justice
National Institute of Justice

This document has been reproduced exactly as received from the person or organization originating it. Points of view or opinions stated in this document are those of the authors and do not necessarily represent the official position or policies of the National Institute of Justice.

Permission to reproduce this ~~copyrighted~~ material has been granted by

Public Domain/FBI
U.S. Department of Justice

to the National Criminal Justice Reference Service (NCJRS).

Further reproduction outside of the NCJRS system requires permission of the ~~copyright~~ owner.



122631

January 13, 1988

TABLE OF CONTENTS

I. DEFINITIONS 1

II. REFERENCES 2

 A. AUTHORITIES 2

 B. GUIDANCE 3

III. INTRODUCTION 3

IV. STATEMENT OF POLICY 5

V. EMPLOYEE NOTIFICATION 10

VI. DRUGS TO BE SCREENED. 11

VII. DETECTION METHOD. 12

VIII. SCOPE OF TESTING. 12

 A. APPLICANT TESTING 12

 B. PROBATIONARY EMPLOYEE TESTING 13

 C. REASONABLE SUSPICION TESTING. 13

 D. RANDOM TESTING. 13

 E. FOLLOW-UP TESTING 14

 F. VOLUNTARY TESTING 14

IX. SPECIMEN COLLECTION PROCEDURES. 14

X. REPORTING PROCEDURES. 18

 A. APPLICANT TESTING 18

 B. TESTING OF ON-BOARD EMPLOYEES 19

XI. EMPLOYEE ASSISTANCE PROGRAM 21

 A. FUNCTION. 21

 B. REFERRAL AND AVAILABILITY 21

 C. EMPLOYEE EDUCATION. 22

XII. SUPERVISORY TRAINING. 22

XIII. SUPERVISORY RESPONSIBILITIES. 23

XIV. SPECIAL DUTIES. 24

 A. DDP COORDINATOR 24

NCJRS

MAR 29 1990

ACQUISITIONS

B.	EMPLOYEE ASSISTANCE PROGRAM ADMINISTRATOR	24
C.	EMPLOYEE ASSISTANCE PROGRAM COORDINATOR	25
D.	EMPLOYEE ASSISTANCE COUNSELOR	26
E.	MEDICAL REVIEW OFFICER.	26
XV.	RECORDS AND REPORTS	28
A.	CONFIDENTIALITY OF TEST RESULTS	28
B.	CONFIDENTIALITY OF RECORDS.	28
C.	EMPLOYMENT ASSISTANCE PROGRAM RECORDS	29
D.	MAINTENANCE OF RECORDS	29
E.	RECORDS MAINTENANCE BY GOVERNMENT CONTRACTORS	29
F.	STATISTICAL DATA.	29
XVI.	DISCIPLINARY ACTIONS.	30
A.	DETERMINATION	30
B.	MANDATORY ADMINISTRATIVE ACTIONS.	30
C.	RANGE OF CONSEQUENCES	30
D.	INITIATION OF MANDATORY REMOVAL FROM SERVICE.	31
E.	REFUSAL TO TAKE DRUG TEST WHEN REQUIRED	31
F.	VOLUNTARY REFERRAL.	31
XVII.	SAVINGS CLAUSE.	31

APPENDICES

Appendix A	Department of Health and Human Services Scientific and Technical Guidelines for Federal Drug Testing Programs.
Appendix B	FBI/DEA Policy Memorandum dated May 7, 1986.
Appendix C	Notification Memorandum to All FBI Employees dated June 3, 1986.
Appendix D	Collection and Chain of Custody Form (FD-716).
Appendix E	FBI Drug Deterrence Program Acknowledgement Form.
Appendix F	Description of Select Support Positions

I. DEFINITIONS

A. Applicant: any individual tentatively selected for employment with the FBI.

B. Drug Deterrence Program (DDP) Coordinator: the individual responsible for the overall management and administration of the DDP within the FBI under the general supervision and direction of the Director.

C. Employee Assistance Program (EAP): The FBI-based counseling program that offers assessment, short-term counseling, and referral services to employees for a wide range of drug, alcohol, and mental health problems, and monitors the progress of employees while in treatment.

D. Employee Assistance Program Administrator: the individual responsible for ensuring the development, implementation and review of the EAP.

E. Employee Assistance Program Coordinator: the individual designated by the EAP Administrator responsible for implementing and operating the EAP within the FBI, by providing counseling, treatment, and education services to employees and supervisors regarding the EAP.

F. Medical Review Officer (MRO): the individual responsible for receiving laboratory results generated from the FBI DDP who has knowledge of substance abuse disorders and the appropriate medical training to interpret and evaluate all positive test results together with an individual's medical history and any other relevant biomedical information.

G. Illegal Drug: a controlled substance included in Schedule I through IV, as defined by section 802(6) of Title 21 of the United States Code (U.S.C.) Controlled Substances Act (CSA), the possession of which is unlawful under Chapter 13 of that Title. The term "illegal drug" does not mean the use of a controlled substance pursuant to a valid prescription or other uses authorized by law.

H. Management Official: an employee required or authorized by the FBI to formulate, determine, or influence the policies of the FBI.

I. Random Testing: a system of drug testing imposed without individualized suspicion that a particular individual is using

illegal drugs in which the employees to be tested are selected from a statistically random sampling of individuals (i.e., Social Security numbers).

J. Supervisor: an employee having authority to direct or assign employees, if the exercise of that authority is not merely routine or clerical in nature, but requires the consistent exercise of independent judgement.

K. Verified Positive Test Result: a test result that has been screened positive by an FDA-approved immunoassay test, confirmed by a Gas Chromatography/Mass Spectrometry (GC/MS) assay (or other confirmatory tests approved by HHS), and evaluated and determined by the MRO not to be justified use of a legitimate drug.

II. REFERENCES

A. Authorities

1. Executive Orders (EO) 12356; 10450 and 12564;
2. Section 503 of the Supplemental Appropriations Act of 1987, Pub. L. 100-71, 101 Stat. 391, 468-471, codified at 5 U.S.C., Section 7301 note (1987) (hereinafter Public Law 100-71);
3. Scientific and Technical Guidelines For Drug Testing Programs, Alcohol, Drug Abuse and Mental Health Administration (ADAMHA), Department of Health and Human Services (HHS), as amended (hereinafter HHS guidelines) (Appendix A);
4. Standards for Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies, Alcohol, Drug Abuse and Mental Health Administration (ADAMHA), HHS, as amended;
5. 42 C.F.R. Part 2, as revised 52 Fed. Reg. 21,796 (June 9, 1987), establishing requirements for assuring the confidentiality of alcohol and illegal drug use patient treatment records;
6. The Privacy Act of 1974, 5 U.S.C., Section 552a, prescribing requirements governing the maintenance of records by agencies pertaining to individuals and access to these records by the individual(s) to whom they pertain (hereinafter Privacy Act);
7. 28 C.F.R. Section 16.40, et seq., implementing the Privacy Act within the FBI;
8. Federal Employees Substance Abuse Education and Treatment Act of 1986; Public Law 99-570;
9. DOJ 1792.1, Employee Assistance Program, May 15, 1978; and related authorities;

10. DOJ 1752.1A, "Discipline and Adverse Action;"
11. DOJ 2610.2, Personnel Security Order, August 18, 1978; and
12. DOJ Drug-Free Workplace Plan (September 25, 1987).

B. Guidance

1. Office of Personnel Management (OPM), Federal Personnel Manual (FPM) Letters 792-16 (November 28, 1986) and 792-17 (March 9, 1987), setting forth guidelines for federal civilian agencies in establishing a drug-free workplace pursuant to EO 12564;
2. FPM Chapter 792, Federal Health and Counseling Programs, providing guidance to federal agencies in establishing alcoholism and illegal drug use programs (subchapter 5) and employee counseling services programs (subchapter 6) for federal employees with alcohol or drug problems; and
3. FPM Supplement, Chapter 792-2, providing guidance for developing and maintaining appropriate prevention, treatment and rehabilitation programs and services for alcoholism and illegal drug use among federal employees.

III. INTRODUCTION

The development of an FBI policy to deter illegal drug use through compulsory urinalysis began in late 1983 after the manager of a large field office voiced a concern over the apparent lack of clearly defined policy in this area. It was suggested that the authority to require employees to submit urine specimens for urinalysis would greatly enhance the ability of managers to identify illegal drug use. It has been a longstanding FBI policy that the abuse of any controlled substance (as defined by the CSA) by an FBI employee would result in severe disciplinary action. See FBI Manual of Administrative Operations and Guidelines (MIOG), Sections 1-2 and 13-2.

Thereafter, the Inspection Division conducted a year long policy review. The product of that review is a December 1984 Office of Program Evaluations and Audits (OPEA) study captioned, "POLICY DEVELOPMENT REGARDING URINE TESTS FOR FBI EMPLOYEES FOR NARCOTICS DETECTION." This study determined, inter alia, that: 1) FBI employees were not immune from societal drug abuse problems; and 2) a formal policy for compulsory urinalysis was desirable.

In 1985, two particular events hastened the development of a comprehensive drug-testing program. First, it was widely reported in the press that major corporations, including approximately one third of the Fortune 500 Corporations, were instituting drug-testing programs, with particular emphasis on pre-employment screening. Private studies had begun to document

the extent of illegal drug use among professional corporate employees and the degree to which it adversely affects the integrity and efficiency of corporate organizations. These studies were of particular concern to the FBI because the FBI recruits professional and clerical employees with social, economic and educational backgrounds similar to the employees recruited by the Fortune 500 Corporations.

Second, the FBI Director and the DEA Administrator determined that the two lead investigative agencies responsible for the enforcement of the federal drug laws should take the initiative and develop model employee drug-testing programs.

By December of 1985, the DEA was well on its way toward the development of a drug deterrence program that would include compulsory urinalysis for Special Agent applicants, for Special Agents during their probationary period of employment, and for select on-board employees on a random basis. The FBI was aware of the DEA's initiative and the Director determined that it would not be desirable to develop two separate policies within the FBI and DEA. Thereafter, it became the intent of both agencies to create a joint drug-testing program modified in its application to suit each agency's individual needs. On May 7, 1986, the FBI and the DEA adopted a joint policy statement that sets forth the details of the FBI/DEA DDP (Appendix B). All employees were notified of the new FBI/DEA policy by the Director's June 3, 1986 Memorandum to All Employees (Appendix C). On July 28, 1986, Agent-applicant testing commenced.

Subsequently, on September 15, 1986, President Reagan signed EO 12564, establishing the goal of a drug-free federal workplace. The Order made it a condition of employment for all federal employees to refrain from using illegal drugs on or off duty. In a letter to all executive branch employees dated October 4, 1986, the President reiterated his goal of ensuring a safe and drug-free workplace for all federal workers.

The EO recognized that illegal drug use is seriously impairing a portion of the national work force, resulting in the loss of billions of dollars each year. As the largest employer in the nation, the federal government has a compelling proprietary interest in establishing reasonable conditions of employment. Prohibiting illegal drug use by employees is one such condition. The FBI is concerned with the well-being of its employees, the successful accomplishment of its missions, and the need to maintain employee productivity. The intent of a drug-testing policy is to offer a helping hand to those who need it, while sending a clear message that any illegal drug use is, quite simply, incompatible with federal service.

On July 11, 1987, legislation was enacted affecting implementation of the EO under Section 503 of Public Law 100-71 in an attempt to establish uniformity among federal agency drug-testing plans, reliable and accurate drug testing, employee

access to drug-testing records, confidentiality of drug test results and centralized oversight of the federal government's drug-testing program.

The purpose of the FBI/DEA DDP is to set forth objectives, policies, procedures and implementation guidelines to achieve a drug-free federal workplace, consistent with the EO and the mandatory guidelines required by subsection (a)(1)(A)(ii) of Section 503 of Public Law 100-71. The intent of Congress and the President is clear: illegal drug use by federal employees, on or off duty, particularly in agencies such as the FBI, is inconsistent with the national security and with the public health and safety.

IV. STATEMENT OF POLICY

It has become increasingly clear that the social, health, and economic costs of illegal drug use in the workplace affect everyone. These costs include human pain and suffering as well as loss of productivity. Illegal drug use can drain one's financial resources. Families, fellow employees, and the American public at large all are affected. Possession of controlled substances without a valid prescription is a federal criminal offense. The impairing physical and psychological characteristics of illegal drug use are well known; the use of illegal drugs adversely affects a person's judgment and response capabilities.

Every FBI employee has a right to a safe and secure workplace. Every American citizen has a right to expect the FBI, which has been charged with enforcing the federal narcotics laws, to be drug free. The public's health, safety and welfare is at risk. It has been a longstanding FBI policy that employees should never cause themselves to be mentally or physically unfit for duty. See MIOG, Section 1-2, supra. The use of illegal drugs is strictly prohibited at any time. As employees of the nation's chief federal law enforcement agency, FBI employees must not themselves engage in criminal conduct. The FBI Personal Conduct Policy Memorandum, dated May 15, 1981, states:

"The FBI must be concerned with the employee's private as well as public personal conduct when such conduct does or could cause impairment of the FBI's efficiency or effectiveness. For example, any conduct which could render an employee vulnerable to inducements to violate law, Department of Justice or FBI rules, regulations, policy or the oath of office is prohibited at all times."

The very nature of the FBI's investigative work and unique mission in the criminal, domestic security, foreign counterintelligence and security-loyalty background areas demands that a high degree of special trust be required not only in the conduct of these investigations but also by all personnel who are involved in the reporting, processing and filing of our

investigative results. The unauthorized dissemination of material or information developed during our investigations or maintained in our files (by employees such as clerk-typists as well as by Special Agents) would significantly affect our mission, endanger the lives or safety of our agents or informants, destroy or diminish their usefulness and invade personal privacy.

Pursuant to OPM guidelines, all positions within the FBI are designated "Critical Sensitive" permitting employees access to classified information. There are a number of reasons for this longstanding policy of the FBI. First, the FBI requires all employees to be cleared for access to classified national security material and information up to and including "Top Secret" on a strict need-to-know basis. The FBI on a regular basis exchanges classified national security material and information with other components of the intelligence community. FBI employees are afforded access to Sensitive Compartmented Information (SCI) which provides for formalized procedures and safeguards established by the intelligence community to ensure access on a need-to-know basis. For these reasons, it is absolutely necessary for all employees to conduct their lives in such a way that they are free from potential blackmail or other possible pressure from agents of foreign governments. EO 10450 captioned, "Security Requirements for Government Employees," EO 12356 captioned, "National Security Information" and Director of Central Intelligence Directive 1/14, dated November 27, 1984, captioned, "Minimum Personnel Security Standards and Procedures Governing Eligibility for Access to Sensitive Compartmented Information," make clear that drug use by federal employees with access to classified information is not consistent with the interests of national security.

Second, Special Agents are subject to reassignment and transfer within the agency at any time for the good of the service. Based on aptitude, interest and place of assignment, Special Agents may be assigned to sensitive intelligence/counterintelligence investigations, either on a full or part-time basis. In larger FBI field office, Special Agents tend to specialize in criminal or intelligence/counterintelligence areas while in the smaller offices Special Agents necessarily must perform in both areas. Also, FBIHQ Special Agents, Special Agents in Charge and Assistant Special Agents in Charge necessarily have supervisory responsibilities covering both criminal and intelligence/counterintelligence areas. The FBI is responsible for investigating compromises of national security material and information. Often these compromises occur in isolated areas of the country where it is necessary for Special Agents to have immediate access to classified information. It is therefore absolutely necessary for all Special Agents to be considered as within the "sensitive" positions characterization of EO 12564.

Third, because the general files of the FBI are not divided based on criminal and intelligence/counterintelligence areas or

classified versus nonclassified areas, it is necessary for clerical employees processing FBI communications and memoranda to have clearance for access up to and including "Top Secret" on a need-to-know basis, thus placing them within the category of "sensitive" positions.

Fourth, many support employees are assigned responsibilities equivalent to those performed by Special Agents of the FBI. For example, the FBI employs translators who necessarily have knowledge of the nature and contents of the intelligence community's most sensitive electronic surveillance. Electronic Technicians and Special Operations Group support employees are engaged in surveillance activities that afford them knowledge of the FBI's foreign counterintelligence sources and methods and areas of investigative interest. Support and service employees are also subject to reassignment within the FBI at any time based on the overall needs of the service. Thus, such employees may be reassigned from criminal support activities to intelligence/counterintelligence activities within a larger office, and in a smaller office may necessarily be required to work both areas simultaneously.

Last, an alteration of our structural organization to permit the establishment of "non-sensitive" positions and the creation of separate physical access areas for those employees assigned to these positions, both at our Headquarters and field offices, would not be cost effective or consistent with our career development programs for both Agent and support and service personnel.

The FBI's law enforcement mission is an equally important basis to ensure that our work force is drug free. The FBI believes that the threat to public safety posed by Special Agents (as well as a wide variety of support employees with investigative duties) who may be illegal drug users is a legitimate factor in establishing a mandatory urinalysis drug-testing program.

Special Agents conduct criminal, domestic security and civil investigations covering numerous classifications of cases over which the FBI has investigative jurisdiction. They are expected to exercise judgment, resourcefulness, versatility, ingenuity, and originality in planning, organizing, and conducting investigations, and must be available for general and special assignment without regard for personal convenience whenever and wherever their services are required. They are also expected to apprehend subjects, many of whom are armed and dangerous and have long records of crimes of violence, and must be willing and able to participate in raids or dangerous or undercover assignments, frequently involving conditions of personal risk. They must be able to operate a motor vehicle at high speed, be able to subdue persons and defend oneself, associates and others as required, possess physical stamina, physical and moral courage, maintain emotional and mental stability and have the capacity to deal effectively with the public. They must be able to operate

scientific crime detection devices and investigative equipment and be skilled in the use of dangerous firearms, explosives and gases. As a result, they must remain alert and in total control of their physical and mental faculties and unencumbered by drugs at all times.

Assignments for Special Agents and many support employees alike necessitate appearing and testifying before courts, grand juries and other judicial and administrative tribunals. Hence, FBI employees who are themselves violating the drug laws would be impeachable and lose all credibility as witnesses. In addition, Special Agents and support employees may be given night, weekend or holiday duty assignments and it is thus imperative that they remain unimpaired by illegal drugs at all times, whether on or off duty.

With the increasing use of computers in law enforcement, support employees have access to a voluminous amount of extremely sensitive information maintained in criminal data banks and to the identities of informants. Agents and support employees alike have access to controlled substances as part of the FBI's CSA investigative authority. Thus, it is extremely important for all employees to be above reproach or pressure from outside influences with interests adverse to the FBI's law enforcement mission. Most importantly, the public's awareness of the use of unlawful drugs by all FBI employees, even off-duty use, detracts from public confidence in the agency. These perceptions of misconduct impair the efficiency of the FBI by making it harder for all employees to perform their law enforcement responsibilities.

The FBI has documented the fact that its Special Agent and support employees are susceptible to illegal drug use. For instance, as part of the OPEA study noted above, the FBI reviewed all drug related administrative inquiries during a fourteen month period from 1982 through 1983. Allegations against nine Special Agents consisted of: 1) failure to report pre-employment drug use; 2) use of marijuana; 3) improper use of a prescribed controlled substance; 4) use of cocaine; and 5) sale of narcotics. At FBI Headquarters alone, the Office of Professional Responsibility (OPR) investigated twenty support employees who were alleged to have engaged in the purchase, sale or use of marijuana while employed with the FBI.

More recent data indicates that drug possession and use remains a concern. During the fourth quarter of 1986, a support employee was dismissed based on a failure to report an arrest for possession of marijuana, admitted use and sale of controlled substances and falsification of official documents. A Special Agent was dismissed based on a failure to disclose pre-employment use of marijuana, admitted on-board use of marijuana, falsification of security questionnaires and a lack of candor. Another Special Agent was disciplined based on a preponderance of evidence which indicated a one-time on-board use of marijuana, falsification of a security questionnaire and lack of candor. Yet a third Special Agent was disciplined for 14 days based on an admitted use of controlled substances with a support employee,

and falsification of Bureau documents regarding the use of controlled substances.

Most disturbing is the fact that despite notice to all Special Agent applicants, as clearly stated in the FBI's recruitment literature and as presented at employment seminars and the like, pre-employment screening has detected a number of individuals who were illegal drug users and who still made an effort to become Special Agents. In the past year, the FBI has tested urine specimens for approximately 2,200 Special Agent applicants and seven verified positive GC/MS test results were recorded. One applicant who tested positive was a retiring military officer. Another applicant was the son of a retired Special Agent. In addition, one applicant attempted to substitute another individual's clean urine specimen.

As a result of the above, and in recognition of the FBI's national security and law enforcement missions, which directly affect public health, welfare and safety, the FBI has an especially compelling obligation to deter and eliminate illegal drug use from its workplace. FBI officials have a legitimate interest in assuring that all employees are not under the influence of illegal drugs and that they are fully capable of performing their duties. This position finds support in the only federal case to date which has considered a challenge to the FBI's employee drug use policy.

"The FBI has a compelling interest in assuring that its agents are not involved in drugs. While all private employers may have a generalize desire to know if their employees' drug use could decrease efficiency, the FBI has far more urgent and compelling needs for such information. FBI agents are privy to highly classified information. Any involvement of an FBI agent with drugs, no matter how small, exposes him to risks of extortion that could jeopardize the national security. Also, since the FBI is charged with responsibility for enforcement of the federal drug laws, illegal drug use by agents risks to corrupt and compromise the agency's discharge of those duties. Furthermore, drug use by an agent could affect the success of an operation implicating important national security law enforcement objectives and could pose risk of injury to other agents working with him. Given these considerations that are vital to national security, I can see no reasonable argument that the FBI committed an unreasonable search in violation of the Fourth Amendment in requesting a urine sample of an agent." Mack vs. United States, 653 F. Supp. 70,75 (S.D.N.Y. 1986), Aff'd., 814 F.2d 120 (2d Cir. 1987).

The FBI believes this summary of the necessity for Special Agents to be unencumbered by the effects of illegal drug use to be equally applicable to all support positions within the FBI. The job functions associated with these positions directly and immediately relate to public health and safety, the protection of life and property and/or to the national security. All FBI

positions are singled out for applicant, random, reasonable suspicion and voluntary testing because the FBI must have the highest degree of trust and confidence in employees in these positions.1

The FBI/DEA DDP therefore established a comprehensive drug testing program which, as applied to FBI employees, consists of the following:

1. the testing/screening of all applicants seeking employment;
2. the testing of probationary Special Agents during the initial first year of employment;
3. the testing of employees when there is reasonable suspicion of illegal drug use;
4. the testing of all employees under a "random testing" program;
5. follow-up testing; and
6. the testing of employees on a voluntary basis.

V. EMPLOYEE NOTIFICATION

By Memorandum to All Employees dated June 3, 1986 (Appendix C), former Director William H. Webster advised all FBI employees of the provisions of the DDP.

A DDP acknowledgment form (Appendix E) has been prepared for presentation to each applicant and employee prior to testing. Each applicant and employee will be required to execute this form with their signature prior to providing a specimen.

A statement in regard to the FBI's DDP has been added to recruitment literature and applications to ensure prospective employees are aware of the FBI policy.

Sixty day notification will be provided to all employees prior to the implementation of random drug testing.

1. In lieu of a Drug Impact Statement, the FBI has identified a number of support positions that would not necessarily be considered particularly sensitive in other agencies but which do rise to the level of critical sensitive in the context of their importance to the FBI (Appendix F).

VI. DRUGS TO BE SCREENED

The FBI testing protocol involves the detection of the following nine categories of drugs²

1. Amphetamines

Amphetamine

Metamphetamine;

2. Barbiturates

Amobarbital

Butabarbital

Pentobarbital

Phenobarbital

Secobarbital;

3. Benzodiazepines

Chlordiazepoxide (Librium)

Diazepam (Valium);

4. Cocaine

Benzoylecgonine;

5. Cannabinoids

Marijuana (THC);

6. Opiates

Codeine

Hydromorphone (Dilaudid)

Morphine (for Heroin)

Oxycodone;

7. Methaqualone

(Quaalude);

8. Phencyclidine (PCP); and

9. Methadone (metabolite).

2. Some of these drugs are listed in Schedule IV and V of the Controlled Substances Act. The FBI has asked the Secretary of

HHS for a waiver of the proposed HHS Scientific and Technical guidelines requirement limiting testing to the detection of Schedule I and II drugs. The request has been taken under consideration by HHS. See October 1, 1987 letter of Acting Director John Otto to Dr. Otis R. Bowers, Secretary, HHS.

VII. DETECTION METHOD

The FBI's DDP urinalysis is performed by a two step screening-confirmation process. The initial screening assay is used to eliminate negative samples and to show which sample may contain a controlled substance.

The initial screening immunoassay (IA) step is a rapid semi-quantitative chemical test which uses a specific antibody to react with the drug or metabolite of interest. The confirmation assay used in the drug analysis procedure is GC/MS, which is scientifically acknowledge to be the most sensitive and accurate method for confirming the presense of drugs in biological samples.

Finally, the MRO will evaluate all positive test results in light of an individual's medical history and other relevant biomedical information.

VIII. SCOPE OF TESTING

The FBI's DDP establishes a comprehensive drug-testing program in the testing/screening of all applicants seeking employment with the FBI, testing of probationary Special Agents during their first year of service, testing of employees when there is "reasonable suspicion" of illegal drug use, the testing of all FBI employees under a random selection program and voluntary testing. In addition, all employees who undergo a counseling and rehabilitation program for illegal drug use through the EAP will be subject to unannounced follow-up testing.

A. Applicant Testing

Urinalysis will be required of all applicants being considered for employment with the FBI. All applicants will be notified of the FBI's DDP and all FBI brochures, literature, handouts, and applications relating to recruitment will contain a statement of FBI DDP policy. Applicants will not be notified in advance of the actual date and time of their drug test. Urine specimens will be obtained by using established collection procedures in accord with mandated HHS guidelines and submitted accordingly. All applicants will be notified that they may be denied employment if test results are positive for illegal drug use or if they fail to provide a urine specimen when required.

B. Probationary Employee Testing

As an acknowledged policy and condition of employment, all probationary Special Agents will be tested during their twelve month probationary period. Unjustified failure to appear for testing or refusal to provide a specimen will be considered refusal to participate in testing and administrative action for insubordination may be initiated.

The probationary employee will not be notified in advance when the sample will be requested. An established collection procedure will be followed in obtaining the urine specimen.

C. Reasonable Suspicion Testing

Reasonable suspicion for this program's purpose is an articulable belief that an employee used or is using illegal drugs drawn from specific and particularized facts and reasonable inferences from those facts.

Reasonable suspicion that an employee uses or is using illegal drugs may be based upon but not limited to:

1. observable phenomena, such as direct observation of drug use or possession and/or the physical symptoms of being under the influence of a drug;
2. a pattern of abnormal conduct or erratic behavior, including abnormal leave patterns;
3. arrest or conviction for a drug-related offense, or the identification of an employee as the focus of a criminal investigation into illegal drug possession, use, or trafficking;
4. information provided either by reliable and credible sources or independently corroborated;
5. evidence that an employee has tampered with a previous drug test; or
6. facts or circumstances developed the course of an authorized investigation of an accident or unsafe working practice.

D. Random Testing

The FBI has a fundamental concern with deterring illegal drug use and will implement random drug testing for all its employees pursuant to EO 12564. For the reasons detailed in Sections III and IV above, all positions within the FBI are deemed to be "test-designated positions" as that term is used in FPM Letter 792-16 (November 28, 1986) and the DOJ Drug-Free Workplace Plan (September 25, 1987). All employees of the FBI will be subject to random testing through a computer generated process of selecting individuals. An employee selected at random will provide a urine specimen for the purpose of drug detection using set collection procedures. It will be stressed to each employee

tested under the random program that he or she is not under any suspicion of taking drugs and that he or she was selected randomly by a computer. Unjustified failure to appear for testing or refusal to provide a specimen will be considered refusal to participate in testing and administrative action for insubordination may be initiated.

E. Follow-up Testing

Follow-up testing, on an unannounced basis, may be required during or after EAP counseling or rehabilitation and for up to one year after completion of rehabilitation.

F. Voluntary Testing

Testing provided at an employee's request.

IX. SPECIMEN COLLECTION PROCEDURES

The following collection procedure will be used for all urine specimens.

Before testing, the collection official will request the individual to be tested (hereafter referred to as the donor) to present suitable photo identification if necessary. If the donor does not have proper identification, this must be noted in the Miscellaneous Section of the FD-716 (Appendix D). The collection official will enter the date, donor's name, Social Security number and time of collection in a log book which is to be maintained at each collection facility. The donor and collection official will sign their names in an appropriate space next to these entries. When not in use the log book will be secured in a locked cabinet or safe and will be afforded the utmost of confidentiality. The donor will receive a thorough briefing during which collection and analysis procedures will be explained, any and all questions answered and a DDP acknowledgment form executed. This form (Appendix E) informs donors of the provisions of the DDP and provides for a donor's voluntary statement of drugs ingested.

If the donor refuses to sign the acknowledgment, the collection official shall note on the acknowledgment form that the donor received the notice. This acknowledgment shall be centrally filed at FBIHQ for easy retrieval by the DDP Coordinator and is advisory only. A donor's failure to sign the notice shall not preclude testing that individual, since the June 6, 1986 Memorandum to All Employees (Appendix C), applicant literature and the random selection 60 day notice will serve as sufficient notification to properly notify all employees and applicants of the drug-testing condition of employment in the FBI.

Social Security numbers will be used as specimen identifying numbers. These number will be utilized to identify the samples throughout the collection, shipping and testing phases of the

urine screening. The purpose of the specimen identifying number is to protect the identity of the donor providing the sample. Laboratory testing personnel will only have access to the identifying number and not the individual's name.

During the collection phase, each donor will be provided with a urine specimen kit containing specimen container, container label and sealing label. The donor and witnessing official will fill out all pertinent information requested on the specimen container label using indelible ink. The collection official in the presence of the donor will: 1) place the donor's Social Security number in the line marked specimen identification; 2) fill in the date; and 3) print his or her name as the collection official in the space provided. The collection official shall have the donor initial in the appropriate space. The name of the donor is not to be placed on this label.

The collection and chain of custody form (FD-716) (Appendix D) will be used to record the specimen collection and to maintain a chain of custody record. The collection official will be responsible for filling in all shaded areas on their form and for signing his/her name in the space provided under chain of custody. Form FD-716 will be provided in triplicate for this purpose. The original FD-716 is to be forwarded to the testing laboratory sealed in the individual collection kit container. The second copy (marked FBIHQ copy) is to be forwarded to FBIHQ, with the DDP acknowledgment form, as enclosures to the weekly communication. The third copy is to be maintained by the field office in a DDP subfile.

The collection official shall request the donor to remove any unnecessary outer garments (e.g., coat, jacket) that might conceal items or substances that could be used to tamper with or adulterate the urine specimen. All personal belongings (e.g., purse, briefcase) must remain with the outer garments. The collection official shall note any unusual behavior or appearance on the part of the donor.

Each donor will be escorted by a collection official of the same sex to the collection area. The donor shall be instructed to wash and dry his or her hands prior to urination. After washing hands, the donor shall remain in the presence of the collection official and not have access to water fountains, faucets, soap dispensers or cleaning agents.

At the collection site, toilet bluing agents shall be placed in the toilet tanks, whenever possible, so the reservoir of water in the toilet bowl always remains blue. There should not be any source of water (shower, sink, etc.) in the enclosure where the specimen is obtained.

EO 12564 directs that donors must be allowed individual privacy when providing specimens unless collection personnel have reason to believe that the individual may alter or substitute the

specimen to be provided. In conformance with this directive, the donor may provide his or her specimen in the privacy of a stall or otherwise partitioned area that allows for individual privacy. The collection official shall note any unusual behavior by the donor.

(If the collection site is a public restroom, the following procedures should be followed: a collection official of the same sex will accompany the donor into the public restroom which must be secured during the collection procedure. Toilet bluing shall be placed into the bowl. The collection official should remain in the restroom, but outside the stall until the specimen is collected. The donor will be asked to void into the disposable specimen container and asked not to flush the toilet until the collection official has received the specimen.)

Direct observation may be made in exceptional circumstances when there is reason to believe a particular individual may alter or substitute the specimen provided.

Reasons to believe a person may alter or substitute the specimen include, but are not limited to:

1. reasonable suspicion that an employee uses illegal drugs;
2. testing as part of or as a follow-up to, counseling or rehabilitation for illegal drug use; and
3. evidence that an employee has tampered with a previous specimen.

Both the donor being tested and the collection official should keep the specimen in view at all times prior to being labeled and sealed. Collection cups will be provided for the convenience of donors. If these cups are used, specimens are to be transferred to the second container by the donor under the direct observation of the collection official. If the donor does not select or is not afforded the option of individual privacy and provides the specimen under the direct observation of the collection official, the above requirement for toilet bluing will not be necessary.

Upon receiving the specimen from the donor, the collection official will determine that it contains at least 60 milliliters (2 oz.) of urine. The donor may be given reasonable amount of liquid (e.g., a glass of water) if unable to provide a specimen. Donors who are unable to provide an adequate specimen initially will remain under observation until able to do so. The collection official is responsible for determining whether the specimen is within normal body temperatures. Any specimen determined to be outside the normal body temperature range will be rejected and the donor requested to provide an additional sample prior to departure. The collection of the subsequent sample is to be conducted under the direct observation of the collection official and circumstances documented by written

communication to FBIHQ. Both specimens will be submitted for analysis.

After the specimen has been provided and submitted to the collection official, the donor should be allowed to wash his or her hands. Once the sample is in the container and capped, the collection official will inspect the specimen container label to ensure it is complete and will request the donor to place it lengthwise across the top and down the sides of the container. The collection official must ensure the container is tightly capped to eliminate leakage.

The collection official must record the appropriate information on the collection form (FD-716). The data and the name of the submitting office must be recorded in the appropriate space. The subject of the communication is to be listed as Drug Deterrence Program: Applicant Testing, Probationary Testing, Random Testing, etc., whichever is appropriate. (The name of the donor, character of the case and file number are not to appear on the FD-716.) The collection official must fill in the specimen number (using the Social Security number of the donor), the date and time of collection and the name of the collection official in the spaces provided. The donor will be requested to identify any prescription or non-prescription medication taken in the past month. The medication and time last taken should be noted in the spaces provided on the FD-716. (The collection official's notation in this section is to be accomplished in addition to the donor's drug ingestion certification on the DDP acknowledgment form.) Medications containing narcotic drugs, hypnotics, stimulants, depressants, sedatives and most muscle relaxers may test positive and should be reported. Drugs such as aspirin, Tylenol, birth control pills, antihistamines, and cold medications except those containing codeine need not be reported. In the event the donor reports taking medication which may test positive, the collecting official should advise the donor that it will be necessary to obtain a copy of the prescription and a statement of verification from the prescribing physician or dentist. The donor may at his or her election give such information to the collection official or should forward the same to FBIHQ, Attention: MRO, Health Services, Administrative Services Division (ASD), DDP, in a sealed envelope.

The donor at his or her election should forward verification information directly to the MRO. In the event no medications are reported, the collecting official is to make a notation of this fact in the Miscellaneous Section of the FD-716. The collection official will place the specimen and the original FD-716 in the container box provided and seal it with the sealing tape provided. The sealed container box(es) will be transferred to the laboratory by the overnight express delivery service.

The collection official is responsible to ensure that a communication providing the name of the donor, Social Security number and date of test is prepared and forwarded to FBIHQ,

Attention: Health Services, ASD, DDP, by Friday of the week in which the specimen was received. To avoid administrative paperwork, the names, etc., of all donors providing specimen within that week may be included in the same communication. The original DDP acknowledgment form signed by the donor must be included as an enclosure to this communication. These and all communications in regard to the DDP are to be sent to FBIHQ, Attention: Health Services, ASD, DDP, in an enclosed envelope.

X. REPORTING PROCEDURES

The following procedures will be utilized in regard to the reporting and disposition of test results received from the testing laboratory:

A. Applicant Testing

Upon receipt of the test results from the testing laboratory, the FBIHQ Health Services DDP Subunit will determine the identity of each donor by comparison of the previously submitted names and identity numbers to the number on each specimen. The Health Services DDP Subunit, by weekly memorandum, will notify the Special Agent and Support Applicant Unit (SASAU) of the names, Social Security numbers and test locations of all applicants who test negative for drugs listed under Section VI, above. Negative test results will not be noted to the field offices. In order to avoid delays in the applicant processing and to eliminate unnecessary administrative correspondence, field offices will continue the applicant processing, subsequent to submitting a urine specimen for drug testing, unless advised to the contrary.

All examinations confirmed positive for drugs will be reviewed by the FBI's MRO prior to the initiation of any official action. If the MRO determines that there is no alternate medical explanation for the positive test, the DDP Coordinator will be notified. A memorandum will be immediately prepared by the DDP Coordinator identifying the donor and describing the drugs identified upon testing. This memorandum will be forwarded to the Director, FBI, Attention: SASAU, and will become a permanent part of the applicant record. Upon receiving a memorandum regarding a verified positive test, the SASAU will immediately notify the field division through which the applicant is being processed to discontinue the processing of that applicant. The SASAU will, over the signature of the Personnel Officer, prepare an appropriate letter notifying the applicant that he or she is no longer being considered for employment.

Inquiries and appeals received from applicants being denied employment with the FBI due to positive drug tests will be handled by the Personnel Officer, ASD. Cases in which illegal drugs, such as marijuana, cocaine or PCP were detected will not be given further consideration for employment with the FBI. In the event that the drug detected was a legitimate prescription drug and the applicant had failed to inform the FBI that he or she was taking

such a drug prior to testing, the applicant may appeal to the Personnel Officer, who will refer the appeal to the MRO for review prior to a final decision. Such appeals will be reviewed on an individual basis taking into consideration the verification of the legitimacy of the drug and possible lack of candor on the part of the applicant.

B. Testing of On-Board Employees

1. Random Selection and Probationary Testing.

Notification of employees to be tested by random selection and Special Agents to be tested within the first year of their probationary period of employment will be made to field offices and Headquarters Divisions by the FBIHQ Health Services DDP Subunit. The field office will follow the established collection procedures and forward collected specimens to the testing laboratory.

Upon receipt of the test results from the testing laboratory, the FBIHQ Health Services DDP Subunit will correlate the test results with the names of the individuals selected for testing. Appropriate records will be maintained regarding negative tests; however, field offices will not be notified of such results in order to minimize administrative burdens.

All examinations confirmed positive for drugs will be reviewed by the FBI's MRO prior to the initiation of any official action. It is the responsibility of the MRO to review all positive test results and medical information provided by the employee in order to determine if there is an alternate medical explanation for the positive test. The MRO may interview the employee, review medical history, consult with laboratory personnel and order retesting as determined necessary. If no alternate medical explanation can be determined, the test will be designated a verified positive by the MRO.

In the event of a verified positive test, the MRO will notify the DDP Coordinator who will prepare an appropriate memorandum outlining the selection procedures and test results. The pharmacological description of the drug and possible legitimate usages will also be outlined in this memorandum. This memorandum, accompanied by a copy of the laboratory report, will be forwarded, through the Assistant Director, ASD, to the Director, FBI, Attention: Assistant Director, Inspection Division, requesting that the Office of Professional Responsibility (OPR) initiate an appropriate investigation.

Investigations conducted by OPR will be conducted in accordance with FBI regulations regarding investigation of employee misconduct. The results of such investigations will be forwarded to the Administrative Summary Unit (ASU), ASD, for review and a recommendation as to appropriate administrative action. The degree of severity of the administrative action will be

determined on a case by case basis, taking into consideration all extenuating or mitigating factors.

A copy of the memorandum prepared in the event of a verified positive test will be forwarded to an EAP counselor who will immediately initiate contact with the employee and extend the assistance and rehabilitation services mandated by EO 12564. In fulfillment of this requirement, a letter will be prepared to the employee outlining the services available and providing names of individuals who can provide guidance and assistance. This letter will be forwarded to the employee by registered mail, return receipt requested.

2. Reasonable Suspicion Testing

If an employee is suspected of using illegal drugs, the first line supervisor will gather all information, facts, and circumstances leading to and supporting this suspicion. The second line supervisor must then decide, after reviewing all documented information with the first line supervisor, if there is enough evidence to substantiate reasonable suspicion. Documentation should contain specific facts and circumstances that lead both the first and second line supervisor to believe that this individual is using illegal drugs. This documentation will then be brought to the attention of the SAC or Division Head who will then determine whether to recommend to OPR that an employee be tested. When such a recommendation is made, a written communication will be prepared to include, at a minimum, the appropriate dates and times of reported drug related incidents, reliable/credible sources of information and any other justification for a test. This communication is to be forwarded to the OPR, FBI Headquarters. It is the responsibility of the Assistant Director, Inspection Division, or his designee to review the facts in each case and to authorize the institution of an investigation and the collection of a urine specimen for testing. All positive urine results will be forwarded to OPR by the MRO after the MRO has conducted the required review to ensure that an alternate medical reason for the presence of the drug does not exist. Verified positive findings of the MRO will be forwarded to the OPR for review. Where testing is conducted based on reasonable suspicion, the urine specimen will be obtained by direct observation by a collecting official of the same sex using set collection procedures. A refusal to provide a specimen will be considered refusal to participate in testing and administrative action for insubordination may be instituted. Following investigation by OPR, the investigative results will be forwarded to the ASU who will act upon each case as outlined under random and probationary testing.

3. Follow-up Testing

Follow-up testing, on an unannounced basis, may be required during or after EAP counseling or rehabilitation and up to one year after completion of rehabilitation. In such cases, the DDP

Coordinator is authorized, at his or her discretion, to initiate the collection of a urine specimen for testing. Thereafter, the reporting procedures will be the same as those detailed for reasonable suspicion testing, including direct observation.

4. Voluntary Testing

In order to demonstrate their commitment to the FBI goal of a drug-free workplace, employees may volunteer for testing by contacting the DDP Coordinator. The DDP Coordinator at his or her discretion is authorized to initiate the collection of a urine specimen for testing. Thereafter the reporting procedures will be the same as those detailed for random selection testing.

XI. EMPLOYEE ASSISTANCE PROGRAM

A. Function

The FBI's EAP provides employees an opportunity, with appropriate assistance, to discontinue their illegal drug use. The program provides educational materials to supervisors and employees on drug use issues, assists supervisors in confronting employees who have performance and/or conduct problems and makes referrals to appropriate treatment and rehabilitative facilities. EAP counselors will follow-up with individuals during the rehabilitation period to track their progress and encourage successful completion of the program. Specifically, the EAP shall:

1. provide counseling and assistance to employees who self-refer for treatment, or whose drug tests have been confirmed positive and who waive their right to confidentiality, and monitor the employees' progress through treatment and rehabilitation;
2. ensure that education and training is provided to all employees on types and effects of drugs, symptoms of illegal drug use and the impact of illegal drug use on performance and conduct, relationship of the EAP with the drug-testing program, and related treatment, rehabilitation, and confidentiality issues; and
3. ensure the confidentiality of counseling, treatment and rehabilitation information and records is maintained in accordance with the law.

B. Referral and Availability

Any employee found to be using drugs illegally shall be referred to the EAP. The EAP shall be available to all employees without regard to a finding of illegal drug use. The EAP shall provide counseling and assist the employee in obtaining private rehabilitation if the employee consents to the release of all such information to the management officials authorized to consider and take action for employee misconduct. If an employee

is dismissed after being referred to the EAP, the EAP Coordinator will advise the individual of the availability of outside rehabilitation service and thereafter remove the employee from the EAP.

C. Employee Education

1. Objectives

The FBI shall offer drug education to all FBI employees. Drug education should include education and training at all levels of the FBI on:

- a. types and effects of drugs;
- b. symptoms of illegal drug use, and the effects on performance and conduct;
- c. the relationship of the EAP to the drug testing program; and
- d. other relevant treatment, rehabilitation, and confidentiality issues.

2. Means of Education

Drug education activities may include:

- a. distribution of written materials;
- b. videotapes;
- c. lunch time employee forums; and
- d. employee drug awareness days.

XII. SUPERVISORY TRAINING

As supervisory/managerial education is an important facet of this program, the FBI is committed to providing managers and supervisors with appropriate training to assist them in identifying and addressing illegal drug use by employees.

A supervisory and managerial training program will be provided in accordance with EO 12564. This training program is designed to assist managers and supervisors to recognize and effectively deal with illegal drug use and its related problems. Such training will include but is not to be limited to:

1. explaining the content and intent of EO 12564 and FPM Letters 796-16 and 796-17;
2. discussing the FBI's overall policy regarding employees who illegally use drugs;

3. helping supervisors recognize behavioral symptoms which may interfere with performance on the job;
4. assisting supervisors on proper documentation of employee performance or behavior;
5. providing guidance regarding how to approach employees suspected of drug abuse; and
6. explaining the function and capabilities of the EAP.

The training program shall contain written material and information which the supervisor can utilize back at the work site.

XIII. SUPERVISORY RESPONSIBILITIES

All supervisors will be trained to recognize and address illegal drug use by employees and will be provided information regarding referral of employees to the EAP, procedures and requirements for drug testing and behavioral patterns that give rise to a reasonable suspicion that an employee may be using illegal drugs. First and second line supervisors shall:

1. be responsible for developing reasonable suspicion of illegal drug use by employees under their supervision after first making appropriate factual observations, documenting those observations and obtaining approval from the next higher supervisor or manager;
2. notify the SAC or Division Head that reasonable suspicion drug tests may be warranted for employees under their supervision; and
3. refer employees to the EAP for assistance in obtaining counseling and rehabilitation when there is a finding of illegal drug use.

The SAC or Division Head shall:

1. be responsible for developing reasonable suspicion of illegal drug use by a direct subordinate after making factual observations and documenting those facts;
2. determine whether a request to test for reasonable suspicion should be made to OPR for any employee under his or her supervision; and
3. ensure that employees under his or her supervision have been referred to the EAP for assistance in obtaining counseling and rehabilitation when there is a finding of illegal drug use.

XIV. SPECIAL DUTIES

A. DDP Coordinator

The DDP Coordinator shall be responsible for implementing, directing, administering and managing the program.

The DDP Coordinator will serve as the principal contact with the drug-testing laboratory in assuring the effective operation of the testing portion of the drug program. The DDP Coordinator will:

1. assure that employees are notified of the scheduling of periodic testing;
2. receive notification from the MRO of verified positive results and refer confirmation to the FBI Personnel Officer for appropriate action;
3. consistent with confidentiality procedures, notify employees testing positive of the availability of EAP counseling and rehabilitation services and provide employees with names and telephone numbers of counselors available for contact;
4. maintain appropriate statistical records, including number of employees and applicants tested and test results;
5. assure that applicants are tested prior to employment;
6. arrange for voluntary testing, and for reasonable suspicion testing when directed;
7. ensure the quality of contract laboratory services and the adequacy of equipment, personnel, and working accommodations through on site inspections and/or review of reports;
8. oversee the life of the contract to assure that the laboratory is accredited and that quality control and chain of custody procedures are adhered to; and
9. remain abreast of the latest technology associated with drug screening and confirmatory testing procedures.

In implementing the education and awareness portion of the DDP, the DDP Coordinator will be responsible for ensuring that:

1. training and education sessions regarding illegal drug use and rehabilitation are scheduled and attended;
2. films, pamphlets and promotional material are publicized and disseminated; and
3. technical aid and assistance is available to implement all parts of the drug awareness program.

B. Employee Assistance Program Administrator

The EAP Administrator (EAA) shall:

1. assume the lead role in the development, implementation, and evaluation of the EAP;
2. supervise and designate the Headquarters EAP Coordinator and counselors and assist them in establishing field office EAP's;
3. oversee the submission of annual statistical reports and prepare consolidated reports on the FBI's EAP activity; and
4. ensure that the appropriate management officials are advised of illegal drug use by employees.

C. Employee Assistance Program Coordinator

The EAP Coordinator shall:

1. implement and operate the EAP within the FBI;
2. provide counseling and referral services to all employees referred to the EAP by their supervisors or upon self-referral;
3. coordinate with the employee and supervisors, as appropriate;
4. work with the DDP Coordinator to provide educational materials and training to managers, supervisors, and employees on the topic of illegal drugs in the workplace;
5. assist supervisors with performance and/or personnel problems that may be related to illegal drug use;
6. monitor the progress of referred employees during and after the rehabilitation period;
7. maintain a list of rehabilitation or treatment organizations which provide counseling and rehabilitative programs, and include the following information on each such organization:
 - a. name, address, and phone number;
 - b. types of services provided;
 - c. hours of operation, including emergency hours;
 - d. the contact person's name and phone number;
 - e. fee structure, including insurance coverage;
 - f. client specialization; and
 - g. other pertinent information;

8. periodically visit rehabilitative or treatment organizations to meet administrative and staff members, tour the site, and ascertain the experience, certification and educational level of staff, and the organization's policy concerning progress reports on clients and post-treatment follow-up; and

9. ensure that the appropriate management officials are advised of illegal drug use by employees.

D. Employee Assistance Counselors

The Employee Assistance Counselor (EAC) shall:

1. serve as the initial point of contact for employees who ask or are referred for counseling;

2. be familiar with all applicable laws and regulations, including drug treatment and rehabilitation insurance coverage available to employees through the Federal Employee Health Benefits Program;

3. be qualified by the EAA and be trained in counseling employees in the occupational setting and identifying drug use;

4. participate in interviews and counseling only after the employee has signed the waiver of confidentiality form;

5. document and sign the treatment plan prescribed for all employees referred for treatment after obtaining each employee's signature on the plan;

6. in making referrals, consider the:

a. nature and severity of the problem;

b. location of the treatment;

c. cost of the treatment;

d. intensity of the treatment environment;

e. availability of inpatient/outpatient care;

f. other special needs, such as transportation and child care; and

g. the preferences of the employee; and

7. advise the EAA of instances of illegal drug use by employees.

E. Medical Review Officer

The role of the MRO is the review and interpret positive test results obtained through the FBI's DDP. This officer will be a

qualified professional with an extensive background in pharmacology and substance abuse. All reports submitted to the MRO should contain the specimen laboratory number assigned by the drug testing laboratory, specimen identification which will be the donor's Social Security number, name of donor, pertinent medical history and results of the drug test. All specimens negative on the confirmatory test shall be reported as negative. Only specimens confirmed positive shall be reported as a positive test for a specific drug. Results may be transmitted to the MRO by various means consistent with the Privacy Act. A certified copy of the original chain of custody form FD-716 signed by the laboratory official shall accompany the report. All analytical results shall be available from the laboratory when requested by appropriate authority. All records pertaining to a given urine specimen shall be retained by the drug testing laboratory for a minimum of 2 years.

Pursuant to the HHS Guidelines, the MRO:

1. may conduct medical interviews with the employee/applicants;
2. may review employee/applicant medical histories or any other biomedical factors;
3. shall review all medical records made available by the tested employee when a confirmed positive could have resulted from legally prescribed medication;
4. shall refer the case to the DDP Coordinator after the laboratory results are verified;
5. may deem that the positive laboratory result is consistent with legal drug use and shall notify the DDP Coordinator accordingly;
6. may deem the results scientifically insufficient for further action and declare the test to be negative based on a review of inspection reports, quality control data, multiple samples, blind controls and other pertinent results; and
7. may order a reanalysis of the original sample if any questions arise as to the legitimacy of a positive test.

Employees who test positive for illegal drugs will be afforded the opportunity to consult with the MRO to provide evidence which may "justify" a positive test result. Employees are not entitled to a trial-type hearing but only an opportunity to provide information orally or in writing to the MRO. Information that may be used to justify a positive result may include but is not limited to:

1. a valid prescription; or

2. an affidavit from the employee's physician verifying a valid prescription.

XV. RECORDS AND REPORTS

A. Confidentiality of Test Results

Laboratory results will be forwarded to the MRO. Any positive result which the MRO justifies by appropriate medical or scientific documentation to account for the result as other than the intentional ingestion of an illegal drug will be reported as a negative test result and may not be released for purposes of identifying illegal drug use. The MRO may maintain only those records necessary for compliance with this program and such records shall be the records of the FBI. Records of the MRO may be released to any supervisor or management official having authority to take adverse personnel actions or for purposes of auditing the activities of the MRO.

In order to comply with the Privacy Act and Section 503(e) of Public Law 100-71, the results of a drug test of an FBI employee may not be disclosed without the prior written consent of such employee, unless the disclosure would be to:

1. the MRO;
2. the EAA when the employee is receiving counseling or treatment or is otherwise participating;
3. any supervisory or management official within the FBI having authority to recommend or approve adverse personnel action against such employee; or
4. a court of competent jurisdiction pursuant to an order of the court and where required by the United States Government to defend against any challenge against any adverse personnel action.

Test results with all identifying information removed shall also be made available to FBI personnel for data collection and auditing.

B. Confidentiality of Records

All drug-testing information specifically relating to individuals is confidential and shall be treated as such by anyone authorized to review or compile program records. All records and information of the personnel actions taken on employees with verified positive test results shall be maintained in accordance with previously established procedures in regard to the maintenance of records of alleged employee misconduct.

C. Employee Assistance Program Records

The EAA shall maintain only those records necessary to comply with program requirements. The EAP will maintain all records necessary to carry out its duties. All medical and or rehabilitation records concerning an employee's drug abuse, including EAP records of the identity, diagnosis, prognosis, or treatment are confidential and may be disclosed only as authorized by 42 C.F.R. Part 2, as revised at 52 Fed. Reg. 21,796 (June 9, 1987), including the provision of written consent by the employee. With written consent, the employee may authorize the disclosure of his or her illegal drug use and information and records of treatment to the employer for the institution of personnel action and for verification of treatment or for a general evaluation of treatment progress.

D. Maintenance of Records

The FBI shall establish or amend a record-keeping system to maintain the records of the DDP consistent with the FBI's Privacy Act System of Records and with all applicable federal laws, rules and regulations regarding confidentiality of records.

If necessary, records may be maintained as required by subsequent administrative or judicial proceedings, or at the discretion of the Director of the FBI. The record-keeping system should capture sufficient documents to meet the operational and statistical needs of legislation and regulations and include:

1. numbers of verified positive test results referred by the MRO;
2. written material justifying reasonable suspicion testing or evidence that an individual may have altered or tampered with a specimen;
3. anonymous statistical reports; and
4. other documents the DDP Coordinator, MRO, or EAA deems necessary for efficient compliance with this program and which satisfy the records and confidentiality requirements of law.

E. Records Maintained by Government Contractors

Any contractor hired to satisfy any part of this program shall comply with the confidentiality requirements of this program, and with all applicable federal laws, rules, regulations and guidelines.

F. Statistical Information

The DDP Coordinator shall collect and compile anonymous statistical data for reporting the number of:

1. random, reasonable suspicion, follow-up, probationary, voluntary and applicant tests;

2. verified positive test results;
3. voluntary drug counseling referrals;
4. involuntary drug counseling referrals; and
5. terminations or denial of employment offers resulting from refusal to submit to testing.

XVI. DISCIPLINARY ACTIONS

A. Determination

An employee may be found to use illegal drugs on the basis of any appropriate evidence including, but not limited to:

1. direct observation;
2. evidence obtained from an arrest or criminal conviction;
3. a verified positive test result; or
4. an employee's voluntary admission.

B. Administrative Actions

The FBI shall immediately refer an employee found to use illegal drugs to the EAP. The FBI shall initiate action to remove or suspend from service any employee the first time that employee is found to illegally use drugs. However, as part of an EAP rehabilitation program, an employee may remain on duty or return to duty if the employee's continued employment would not endanger public health and safety or national security.

C. Range of Consequences

In determining the severity of the disciplinary action to be taken against an employee found to use illegal drugs, the FBI may consider the nature of the position, the risk to the public of the employee's illegal drug use, and the employee's personnel and/or performance records. The FBI shall initiate disciplinary action against any employee found to use illegal drugs, provided that such action is not required for an employee who voluntarily admits to illegal drug use, obtains counseling or rehabilitation and thereafter refrains from using illegal drugs.

Such disciplinary action may include any of the following measures, but some disciplinary action must be initiated:

1. reprimand the employee in writing;
2. place the employee in an enforced leave status;
3. suspend the employee for 14 days or less;

4. suspend the employee for 15 days or more;
5. suspend the employee until he or she successfully completes the EAP or until the FBI determines that action other than suspension is more appropriate; or
6. dismiss the employee from the FBI.

D. Initiation of Mandatory Removal From Service

The FBI shall initiate action to dismiss an employee for:

1. refusing to obtain counseling or rehabilitation through the EAP as required by the EO 12564 after having been found to use illegal drugs; or
2. having been found not to have refrain from illegal drug use after a first finding of illegal drug use.

E. Refusal to Take Drug Test When Required

An employee who refuses to be tested when so required will be considered insubordinate and subject to the full range of disciplinary action, up to and including dismissal. Attempts to alter or substitute the specimen provided will be deemed a refusal to take the drug test when required. No applicant who refuses to be tested shall be extended an offer of employment.

F. Voluntary Referral

Pursuant to EO 12564, the FBI is required to discipline any employee found to use illegal drugs in every circumstance except one: If an employee (1) voluntarily admits his or her drug use; (2) completes counseling and rehabilitation through the EAP; and (3) thereafter refrains from drug use, such discipline is not required and may be waived.

The decision whether to discipline a voluntary referral will be made on a case-by-case basis depending upon the facts and circumstances. Although an absolute bar to discipline cannot be provided because of the extreme sensitivity of all FBI positions, the FBI, in determining whether to discipline, shall consider that the employee has come forward voluntarily.

XVII. SAVINGS CLAUSE

To the extent that any of the procedures specified in this DDP are inconsistent with any of those specified in the HHS guidelines (Appendix A), or any subsequent amendment thereto, such HHS guidelines or amendment shall supersede the procedures specified in this DDP, but only to the extent of the inconsistency.

APPENDIX A

Department of Health and Human Services
Scientific and Technical Guidelines for Federal
Drug Testing Programs

Federal Register

**Monday
April 11, 1988**

Part IV

**Department of
Health and Human
Services**

**Alcohol, Drug Abuse, and Mental Health
Administration**

**Mandatory Guidelines for Federal
Workplace Drug Testing Programs; Final
Guidelines; Notice**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Alcohol, Drug Abuse, and Mental Health Administration

Mandatory Guidelines for Federal Workplace Drug Testing Programs

AGENCY: National Institute on Drug Abuse, HHS.

ACTION: Final Guidelines.

SUMMARY: The Department of Health and Human Services (DHHS) adopts scientific and technical guidelines for Federal drug testing programs and establishes standards for certification of laboratories engaged in urine drug testing for Federal agencies.

EFFECTIVE DATE: April 11, 1988.

FOR FURTHER INFORMATION CONTACT: Maureen Sullivan (301) 443-6780.

SUPPLEMENTARY INFORMATION: These Final Guidelines, titled "Mandatory Guidelines for Federal Workplace Drug Testing Programs" were developed in accordance with Executive Order No. 12564 dated September 15, 1986, and section 503 of Pub. L. 100-71, the Supplemental Appropriations Act for fiscal year 1987 dated July 11, 1987. The statute specifically requires that notice of proposed mandatory guidelines be published in the *Federal Register*; that interested persons be given not less than 60 days to submit written comments; and that after review and consideration of written comments, final guidelines be published which:

I. Establish comprehensive standards for all aspects of laboratory drug testing and laboratory procedures to be applied in carrying out Executive Order No. 12564, including standards which require the use of the best available technology for ensuring the full reliability and accuracy of drug tests and strict procedures governing the chain of custody of specimens collected for drug testing;

II. Specify the drugs for which Federal employees may be tested; and

III. Establish appropriate standards and procedures for periodic review of laboratories and criteria for certification and revocation of certification of laboratories to perform drug testing in carrying out Executive Order No. 12564.

Subpart A of this document contains general provisions. Subpart B, titled "Scientific and Technical Requirements," responds to the mandates in items I and II above. Subpart C, titled "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," responds to item III.

In substance, these Final Guidelines are very similar to those in the Notice of Proposed Guidelines published on August 14, 1987 (52 FR 30638). However, significant editorial and format changes have been made. The Guidelines have been edited as a single, integrated document organized in a more traditional format with subparts, numbered sections, and consistent paragraph designators. Definitions have been grouped together in Subpart A. Rather than repeat identical material, the document contains internal cross-references, particularly from Subpart C to Subpart B. This new organizational approach should add clarity to presentation of the material and aid the cross-referencing and citation of individual sections and paragraphs.

Prior to addressing comments on the specifics of the scientific and technical requirements and the certification program, it is worth noting that a number of commentators perceived the laboratory standards in these Guidelines as redundant, viewing existing regulations, guidelines, and certification/licensure mechanisms of the Medicare and Clinical Laboratory Improvement Act of 1967 (CLIA) interstate licensure program—also administered by DHHS—as sufficient to provide quality assurance for urine drug testing laboratories.

The Medicare and CLIA certification requirements apply to laboratories conducting a wide range of medical tests, having been designed for any medical testing laboratory receiving Medicare/Medicaid reimbursement or performing testing on specimens in interstate commerce, respectively.

The laboratory portion of the President's Drug-Free Federal Workplace Program can be distinguished from the Medicare/CLIA programs by important differences in policies, procedures, and personnel arising from standards appropriate to the application of analytical forensic toxicology for this program. Unique distinguishing features include:

- Rigorous chain of custody procedures for collection of specimens and for handling specimens during testing and storage.
- Stringent standards for making the drug testing site secure, for restricting access to all but authorized personnel, and providing an escort for any others who are authorized to be on the premises;
- Precise requirements for quality assurance and performance testing specific to urine assays for the presence of illegal drugs; and
- Specific educational and experience requirements for laboratory personnel to

ensure their competence and credibility as experts on forensic urine drug testing, particularly to qualify them as witnesses in legal proceedings which challenge the finding of the laboratory.

Medicare and CLIA laboratory certification procedures do not provide for quality assurance and performance testing specific to urine drug testing laboratories. With few exceptions, the Medicare and CLIA certification programs do not have employees specifically trained in toxicology to perform the on-site surveys and evaluations of the laboratories and the technologies employed in the laboratories. The Medicare and CLIA standards do not address issues such as cutoff limits for drug detection, grading criteria for the performance testing programs, blind performance testing requirements, specifications for the analytical techniques to be employed, types of drugs to be detected (including metabolites), and detailed outcome measures of performance such as requiring assays of quality control samples and a large number of performance test samples as an initial and ongoing requirement for certification.

The need to assure the protection of individual rights within the context of a drug testing program—linked to both employee assistance programs and the management potential for taking adverse action against an employee—makes essential the development of a separate laboratory certification program to respond to the unique requirements of the program mandated by the President and the Congress. These Guidelines set standards for such a certification program.

The Final Guidelines make clear that they do not apply to drug testing under any legal authority other than E.O. 12564, including testing of persons under the jurisdiction of the criminal justice system, such as arrestees, detainees, probationers, incarcerated persons, or parolees (see § 1.1(e)). The testing of persons in the criminal justice system is different than testing under E.O. 12564 for several reasons: (1) The overriding purpose of the criminal justice system is to protect community safety through the apprehension, adjudication, and punishment of law violators; (2) the incidence of drug use among those under the jurisdiction of the criminal justice system is high; and (3) the legal interests at issue in the criminal justice system, including liberty, privacy, and property interests, are different and, therefore, are subject to established practices, constitutional protections, and evidentiary rules specific to the criminal

justice system. The Guidelines also do not apply to military testing of service personnel or applicants to the military.

Response to Comments

Written comments to the Notice of Proposed Guidelines published August 14, 1987, were received from approximately 150 individuals, organizations, and Federal agencies. All written comments were reviewed and taken into consideration in the preparation of the Final Guidelines. This section summarizes major comments and the Department's response to them. Similar comments are considered together.

1. Several commenters requested that the Guidelines require a split sample technique in which a second sample or a portion of a sample could be saved for further testing. Although this possibility was considered, it is viewed as a cumbersome and expensive process involving the collection of two separate sets of samples and the retention of one for an indefinite period of time in some type of secured long term refrigerated storage. The use of a split sample was suggested as a mechanism to overcome perceived problems arising out of situations such as sample mixups, erroneous identification of samples, and lost samples. The Department does not agree that split or additional sample proposal would have any scientific advantage over the current system nor would they increase reliability. In fact, such a system could increase the risk of administrative error by doubling the labeling, initialing, storage, and accountability requirements. Furthermore, the Guidelines already include sufficient safeguards to eliminate the problems the use of split or additional samples are thought to address; e.g., detailed safeguards for labeling and chain of custody of the urine sample. Accordingly, we do not project any real scientific, chain of custody, or reliability benefits sufficient to justify placing the added requirement of collection and storage of split samples of Federal agencies and have rejected the split sample requirement. Furthermore, these Guidelines specifically reject allowing the tested employee or anyone else from presenting to the Medical Review Officer a split sample or private sample that does not fully comply with these Guidelines.

2. A number of commenters said that specific educational and experience requirements for laboratory directors and supervisors were too restrictive and that specific board certifications, experience, and degree requirements were also too restrictive and did not

provide any additional quality assurance. In many cases these individuals recommended that the current Medicare and CLIA personnel standards be used in place of the standards proposed in the Guidelines. Other individuals and organizations stated that the proposed personnel standards in the Guidelines were not stringent enough. Some recommended that specific standards also be adopted for the personnel performing the tests.

The Department carefully considered the comments about the personnel standards proposed in the Guidelines—most of which came from employees of clinical laboratories or organizations representing those employees—from the perspective of the intent of the Guidelines. It is not possible to reconcile the divergent viewpoint represented in the comments. In this connection it should be noted that credentialing standards for laboratory personnel have been an issue for a number of years in other laboratory programs administered by DHHS, as well as among those who commented on the Notice proposing these Guidelines.

The laboratory personnel requirements in the Guidelines are designated to assure that any individual responsible for test-review and result-reporting is qualified to perform the function and could appear as an expert witness in a court challenge of the results. This requires familiarity with a wide range of material related to test selection, quality assurance, interferences with various tests, maintenance of chain of custody, documentation of findings, interpretation of test results, validation and verification of test results, and the ability to testify as an expert in legal proceedings. The Guidelines set personnel requirements for the individuals responsible for day-to-day management and operation of laboratories engaged in urine drug testing for Federal agencies aimed at ensuring those competencies.

While a consultant may be able to carry out some of these specialized functions, it is essential that comprehensive oversight and control of the responsibilities cited above be exercised by those who are directly responsible on a day-to-day basis for the laboratory, who are accountable for the test results, and who may be called on to consult with the agency for which testing is performed as well as to appear at any legal proceeding to defend the quality of testing in the laboratory. Therefore, the Guidelines set functional employee qualification standards which are essential to the mission of a drug

testing laboratory and require that laboratory employees meet those standards. For the purpose of meeting laboratory personnel requirements, no provision is made for the use of consultants who are not involved in the day-to-day management or operation of the laboratory.

The Final Guidelines set functional requirements for individuals engaged in the day-to-day management and operation of laboratories engaged in urine drug testing for Federal agencies. They do not specify requirements for other personnel, including employees who perform the assays, but rather depend on the ability of those responsible individuals to select and oversee properly qualified employees in each specific laboratory, and they depend on outcome measures of laboratory performance such as performance testing. The individual responsible for day-to-day laboratory management is responsible for determining staffing needs and types of personnel required to perform particular functions in a specific facility. The individual responsible for day-to-day laboratory operations is responsible for supervision of analysts performing drug tests and related duties. Outcome measures will provide the responsible individual with feedback on the performance of laboratory employees. Within this framework, the Guidelines do not establish qualifications for additional laboratory positions.

The individuals who perform the tests are a vital part of any laboratory operation, and there is no intent to minimize their importance by omitting qualifications for them. However, by holding the appropriate laboratory officials responsible for review and certification of all test results before they are sent forward and by relying on various quality control and quality assurance measures, performance testing and on-site evaluations to provide direct measures of the quality of testing, the Department expects to ensure a standard of excellence in drug testing without setting additional personnel requirements. This reliance on the qualifications of the individuals responsible for the day-to-day management and operation of urine drug testing laboratories does not prohibit the laboratories themselves from setting additional employee standards which may include specific credentials, certifications, licenses, registries, etc., for specific functions.

However, once a laboratory is certified in accordance with these Guidelines, laboratory employees whose functions are prescribed by these

Guidelines are deemed qualified. These Guidelines establish the exclusive standards for qualifying or certifying these employees involved in urinalysis testing. Certification of a laboratory under these Guidelines shall be a determination that all appropriate qualification requirements have been met. Agencies may not establish or negotiate additional requirements for these laboratory personnel.

Some commentors felt that references to director, supervisor of analysts, certifying officials, and other analysts did not clearly distinguish between those positions. Other commentors criticized the establishment of specific position titles. We have clarified laboratory employee functions and dropped the use of specific position titles in 2.3 Laboratory Personnel. A laboratory engaged in urine drug testing for Federal agencies must have personnel to perform the following functions:

- Be responsible for the day-to-day management and for the scientific and technical performance of the drug testing laboratory (even where another individual has overall responsibility for an entire multispecialty laboratory).
- Attest to the validity of the laboratory's test reports. This individual may be any employee who is qualified to be responsible for the day-to-day management or operation of the drug testing laboratory.
- Be responsible for the day-to-day operation of the drug testing laboratory and for the direct supervision of analysts performing drug tests and related duties.

In response to those commentors who were concerned about the proposed requirement for a Ph.D. to qualify as a laboratory director, the Final Guidelines provide that the individual responsible for the day-to-day drug testing laboratory management may have education and experience in lieu of a Ph.D. to demonstrate an individual's scientific qualifications in analytical forensic toxicology (see 2.3(a)(2)(iii)). Together with the specific analytical forensic toxicology experience required in 2.3(a)(2)(iv), scientific qualifications may be demonstrated by showing "training and experience comparable to a Ph.D. in one of the natural sciences, such as a medical or scientific degree and in addition have training and laboratory or research experience in biology, chemistry, and pharmacology or toxicology." This Ph.D. comparability provision eliminates the utility of the "grandfather" clause in the proposed guidelines, a clause which would have qualified incumbent laboratory directors who have a graduate degree in the

natural sciences followed by extensive experience (6 years postgraduate), in analytical forensic toxicology. Thus, the Final Guidelines omit the "Grandfather" clause.

The Ph.D. comparability provision, while not requiring specific research experience, recognizes research as one mechanism for demonstrating scientific competency to be responsible for day-to-day laboratory management. Lack of research experience does not disqualify an individual for that function if he or she has other appropriate training or experience. The Ph.D. comparability provision also makes explicit that a medical degree is an acceptable alternative to the Ph.D. for this purpose, provided, of course, that the M.D. has the other requisite training and experience.

The Final Guidelines do not require specific board certification for any laboratory employees. Some commentors were concerned particularly that individuals who supervise analysts would have to be on the registry of the American Society for Clinical Pathologists (ASCP). The proposed guidelines cited the ASCP registry, but only as an example of the type of experience and education that would qualify an individual to oversee the day-to-day operations of a urine drug testing laboratory, including the supervision of analysts. The important factors associated with day-to-day operation and supervision of analysts in a forensic toxicology laboratory are captured in 2.3(c). Therefore, the Final Guidelines omit any reference to a registry as a factor in qualifying an individual for this function. Likewise, the Guidelines do not refer to a registry for the individual responsible for day-to-day laboratory management or the individual responsible for attesting to the validity of the laboratory's test reports, but rely instead on education and experience qualifications set out in 2.3 (a) and (b), respectively.

Consistent with editorial revisions throughout the Final Guidelines, editorial changes in the personnel provisions are intended to clarify specific education, training, and experience requirements for individuals to carrying out vital laboratory functions, to simplify by adopting consistent terminology, and to eliminate the need to compare similar provisions by using identical provisions when appropriate. In this regard, the personnel provisions in Subpart B, which sets out the scientific and technical requirements, and in Subpart C, which sets out the standards for certification of laboratories, are identical: Subpart C

simply cross-references the personnel provisions in Subpart B.

3. A number of commentors said that it was unnecessarily restrictive to require that the screening and confirmation tests be performed at the same site. They believed that the majority of tests would be negative and that would reduce the number of samples that must be shipped to another site and would, in turn, prevent sample mixup and loss.

After having carefully reviewed this issue, the Department has determined that both screening and confirmatory testing must be performed at the same time (3.5). Although use of separate screening and confirmation laboratories may produce adequate results, Pub. L. 100-71 mandates that the Secretary set standards which "require * * * strict procedures governing the chain of custody of specimens collected for drug testing." Same-site screening and confirmation is the best method for maintaining such strict control in the chain of custody.

Requiring the two tests to be performed in the same laboratory will reduce problems inherent in having two test sites, such as problems maintaining chain of custody forms at two test sites; need for having two separate laboratory forms; possible mix-ups and loss of samples in transit between sites; potential delays in reporting results; and potential for having results reported only on the basis of an initial screening test.

Several commentors indicated that if screening were done on-site this would reduce the number of subsequent requirements for rescreening and result in fewer samples being sent to another site. The Federal work force testing program does not envision performing initial tests at the collection site. Therefore, considerations concerning on-site initial screening tests are not relevant to the current Federal testing program.

4. Several commentors indicated that a number of terms were not defined or that there was no single section defining terms used in the Notice of Proposed Guidelines. The Final Guidelines include a section to centralize the definitions that appeared in the proposed document and add definitions to several previously undefined terms (1.2). The term "proficiency testing" has been edited throughout to read "performance testing" as a more precise reflection of the nature of the testing with which these Guidelines are concerned.

5. A number of commentors said that the cutoff limits for the reporting of positive results should be higher or

lower than those proposed (see 52 FR 30641). There also were commentors who believed that the cutoff limits for the screening and confirmation tests should be set at the same level.

The initial immunoassay test cutoff is established at levels generally similar to those used by the Department of Defense and available with commercial immunoassays. These levels are consistent with detection of recent drug use.

The second set of cutoff levels is for the gas chromatography/mass spectrometry (GC/MS) confirmatory test, chosen so that the specimens determined to be positive by the first technique (screening technique) could be confirmed at a reasonable level of analytical accuracy.

The Final Guidelines retain all the proposed initial test cutoff values (2.4(e)). Confirmation for marijuana is changed by 5 ng/ml in accordance with DOD experience. Likewise, confirmation for amphetamines reflects the cutoff intended for the notice of proposed guidelines consistent with DOD levels. Cutoffs for specific opiates (morphine and codeine) and amphetamines (amphetamine and methamphetamine) are delineated for clarity (2.4(f)).

In finalizing both screening and confirmation cutoffs, among the matters considered were prevalence rate; cross-reactivity; state of the art in drug detection; and the experience of the Department of Defense and other groups in large-volume drug testing programs.

6. Several commentors indicated that alcohol should be included among the substances to be tested. The Department acknowledges the significance of alcohol and its use as well as its potential impact on performance in the workplace. In any event, alcohol is not an illegal substance, and Executive Order 12564, which these Guidelines implement, only authorizes testing for illicit drugs listed in Schedule I and Schedule II of the Controlled Substances Act. However, nothing in these Guidelines restricts the authority of agencies to test for alcohol under authorities other than E.O. 12564.

7. Several commentors indicated that photo identifications should be required at the testing site to ensure that the tested individual is properly identified. We concur that proper identification should be provided by the individuals at the test site to assure that the correct individual will be tested. Since most Federal agencies already issue photo identification cards to their employees and most employees have a driver's license with photo identification, it is not unreasonable to require this form of identification for individuals presenting

themselves for testing. In cases where the individual does not have a proper photo identification, the collection site person must get the employee's supervisor, coordinator of the drug testing program, or any other agency official who knows the employee to provide a positive identification (2.2(f)(2)).

8. Several commentors suggested that toilets, water faucets, and other sources of water which could be used as adulterants should be taped shut or sealed to prevent adulteration of the sample at the collection site. The Department acknowledges that sources of water should not be available which would enable an individual to adulterate the sample. However, there are also needs, such as hand washing, for a relatively convenient source of water. These Guidelines cannot anticipate the needs at each collection site and the hardship which would be imposed by sealing all sources of water at the site. However, the proposed and Final Guidelines do include in 2.2 precautions in specimen collection procedures to ensure the integrity and identity of the specimen. Because we have taken reasonable steps to ensure that specimens are not adulterated at the collection site and because there are practical reasons for having a convenient source of water, the Final Guidelines do not require that all sources of water be taped or sealed shut but rather require that precautions be taken to ensure that unadulterated specimens are obtained. Among the precautions included in 2.2(f) to ensure unadulterated specimens is a requirement to use a bluing agent so that the water in the toilet tank and bowl are colored blue and that there be no other source of water in the enclosure where the sample is given.

9. Several commentors requested more specific guidelines to define "unusual behavior" at the urine collection site which would give reason to believe a particular individual may alter or substitute the specimen to be provided which, in turn, would trigger the requirement to obtain a second specimen under direct observation of a same gender collection site person (see 2.2(f)(16)). The guidelines focus on whether there is "reason to believe" (see 1.2 for definition) that a sample is adulterated. Observations of unusual behavior may bear on whether there is a "reason to believe" and for that reason the Guidelines require such observations to be documented in the permanent record book. While it may be desirable to provide specific descriptions of or guidelines to identify "unusual behavior," the Department

cannot foresee or define every contingency which might occur. Thus, "unusual behavior" is not further defined in the Guidelines.

It should be noted, however, that other indicia of "reason to believe" are set out in 2.2(f). For example, 2.2(f)(12) and (13) require a temperature reading upon collection of the specimen and indicate those temperatures which would give rise to a reason to believe that a specimen may be altered or substituted. Elsewhere the Guidelines require the collection site person to inspect the sample for unusual color or other signs of contaminants (2.2(f)(14)). Likewise, if a collection site person sees unusual behavior which causes him or her to question the integrity of the sample such that it leads to a reason to believe that a particular individual may alter or substitute the specimen to be provided, the Guidelines require that such an observation be noted in writing in the permanent record book (2.2(f)(8)). The Final Guidelines also add a requirement that any "reason to believe" observation be concurred in by a higher level supervisor of the collection site person (2.2(f)(23)).

With regard to reason to believe that a particular individual may alter or substitute the specimen based on the specimen's temperature falling outside the acceptable range, the Final Guidelines permit an individual to volunteer to have an oral temperature reading to provide evidence that the temperature of the specimen was consistent with the individual's body temperature, i.e., an individual's fever could cause an elevation in the temperature of the specimen (2.2(f)(13)).

10. Several commentors said that if the first specimen is subject to a reason to believe that the particular individual may alter or substitute the specimen which would require a second specimen to be collected, the second specimen should be collected immediately. The Department concurs that the second specimen should be collected as soon as the need for it is established. Therefore, the Guidelines provide that the second specimen shall be collected as soon as possible whenever there is reason to believe that the particular individual may alter or substitute the specimen. (2.2(f)(16)).

11. Several commentors wanted to know the basis for the choice of cocaine and marijuana as the drugs required to be screened by all agencies. The requirement that all agencies screen for cocaine and marijuana was based on the incidence and prevalence of their abuse in the general population and the experiences of the Department of

Defense and the Department of Transportation in screening their work forces. The choice of cocaine and marijuana as the only substances for which all agencies must test takes into account that the predictive value of any positive diagnostic test is a function of prevalence in the tested population. Agencies have also been authorized to test for phencyclidine, amphetamines, and opiates because their high incidence and prevalence in the general population may warrant testing of particular agency work forces for these illegal substances (2.1(a)).

Federal agency requests for screening drugs other than the five authorized in these Guidelines must be made in writing to the Secretary. The Secretary will review the requests on a case-by-case basis and make a determination of the acceptability of the plans, cutoff limits, and testing protocols. The Secretary's determination shall be limited to the use of appropriate science and technology and shall not otherwise restrict agency authority to test for drugs included in schedules I and II of the Controlled Substances Act (2.1(b)).

12. Several commentors wanted clarification of the procedures for the Medical Review Officer's (MRO's) protocols for performing the review function. They also wanted to know if individual employees would have an opportunity to discuss the Medical Review Officer's findings with him or her. Procedures for the conduct of the medical review function, including a handbook to cover the activities of the MRO, will be disseminated to all Federal agencies. While there is agreement that there should be an opportunity for some type of medical interview between the medical review officer and the employee prior to the MRO's final decision concerning a positive test result, a face-to-face interview may not always be feasible or possible. For example, they may be in widely distant geographic areas, and it may be more practical to arrange a telephone or teleconference interview than a direct meeting. Therefore, we have provided for flexibility in the mechanism for this communication and have stated at 2.7(c) that prior to making a final decision to verify a positive result, the MRO shall give the individual employee an opportunity to discuss the test result with him or her. The Medical Review Officer shall not, however, consider the results of urine samples that are not obtained or processed in accordance with these Guidelines.

13. Several commentors indicated that color blindness measurements for laboratory workers were not necessary

since none of the currently approved methodologies involved the use of visual color measurements. The requirement that laboratories maintain files which include information on employee color vision was originally proposed because some immunoassay systems have color-coded components and the reliable manipulation of such systems requires good color vision. In view of the methodologies currently approved in the Guidelines, we agree that an across-the-board requirement to maintain files on color blindness is not warranted. However, the Department has a more general concern that laboratories employ individuals who have the ability to perform any necessary test procedures. Therefore, the Guidelines generally provide at 2.3(f) that laboratory personnel files shall include results of any tests which establish employee competency for the position he or she holds and provide, as a specific example, a test for color blindness if the employee will be using color coded analytical systems. Similarly, the final Guidelines do not require that laboratories maintain any other medical data about employees unless that data would be necessary to show the employee's competency to perform a specific job function.

While these Guidelines do not require laboratories to maintain general health or medical information in employee files, they do not preclude a laboratory from maintaining such files. What 2.3(f) is intended to do is require laboratories to maintain sufficient files to show employee competency for the position he or she holds.

14. One commentor requested that the laboratory notify agency management officials of a positive result at the same time the Medical Review Officer is notified, so that individuals in sensitive positions or in positions where they could pose a hazard to other individuals or the public could be temporarily removed from these positions, with no punitive action, until after the Medical Review Officer had completed the review process. After considering both the safety implications and the employee rights in this type of notification, the Department has determined that it would be inappropriate to report a result before the Medical Review Officer has the opportunity to review the facts and circumstances and make a decision on the meaning of the test results. In instances where an agency determines that it has a need for immediate action or might have such a need based on its mission, the agency should develop a mechanism to expedite the review

process or allow the Medical Review Officer to require review of the individual's general fitness to continue performing a specific function. Circumventing the review system would abridge necessary protections for employees and could result in prejudging an individual employee's case (2.7).

15. Several commentors called for a medical review board instead of a single Medical Review Officer. A primary purpose of the Medical Review Officer position is to provide for the privacy and confidentiality of the employee's personal medical history during the course of reviewing positive test results. To call together a board which would be privy to that private information would increase the exposure of the employee's medical history to several other individuals. Furthermore, the Department views the physician in the Medical Review Officer's role in retaining overall responsibility for reviewing and interpreting positive test results. There is no restriction on the Medical Review Officer's seeking advice on an ad hoc or a continuous basis from an individual or group if he or she does not breach employee confidentiality during the course of the review and interpretation of the employee's test results. Because the Department is vitally concerned with maintaining confidentiality and privacy and because the Medical Review Officer is not now limited in seeking advice from persons who might have served on the proposed medical review board (e.g., the drug program coordinator, employee assistance program officials, or any other agency employee), the Guidelines will continue to call for review by a single medical officer rather than a board (2.7).

16. Several commentors requested that the term "inexpensive immunoassay" to describe the initial test be eliminated since cost should be left to the agency and the laboratory and techniques other than immunoassay should be used to test for certain drugs. The term "inexpensive" was not intended to set specifications for price; that is a matter for negotiation between the laboratory and the contracting Federal agency. It was meant to serve as part of a generic description of the procedure and purpose of a screening assay. The term "initial test" has been revised in 1.2 and does not use the word "inexpensive".

17. Several commentors indicated that more specific guidelines should be issued to assure the security of test results whether sent by mail or by electronic means. The Guidelines clarify

that the laboratory must ensure the security of data transmission and limit access to any data transmission, storage, and retrieval system (2.4(g)(4)).

18. Several commentors stated that individuals should have access to all records, data, and documents relating to their test results and the certification of the laboratory which performed the urine drug test. Section 503 of Pub. L. 100-71 provides that any Federal employee who is the subject of a drug test shall, upon written request, have access to any records relating to his or her drug test and any records relating to the results of any relevant certification, review, or revocation-of-certification proceedings. In response to this comment the provisions of the statute have been set out in a new paragraph at 2.9. The Department anticipates that individuals will be able to obtain information about their own test results from the agency's Medical Review Officer, employee assistance program, or other staff person designated by the agency. Any other relevant information will be made available in accordance with the statute.

19. Several laboratories indicated that the monthly statistical summary required of the testing laboratories would be costly and an excessive burden. The Department views the monthly data as necessary for several purposes including evaluating the laboratory testing program, gathering statistical data to evaluate the drug testing program's effectiveness, and providing demographic data on drug use by the Federal work force. The information will assist in making decisions concerning changes in policy or program implementation and identifying specific programs for attention. The Department anticipates that the cost of providing the data will be built into the contract the laboratory signs with each agency. Therefore, provision of the data will be a function for which the laboratory is duly compensated, not an undue cost or burden (2.4(g)(6)).

20. One commentor indicated that samples for which the initials on the specimen bottle and in the permanent record book do not match should not be rejected automatically, since this would provide an opportunity for individuals to attempt to have their specimens rejected when they knew the specimens would test positive. We have considered the fact that individuals might deliberately alter their initials in an attempt to have their samples rejected. However, we do not anticipate that samples should be thrown out solely on the basis of unmatched initials on the specimen

bottle and in the permanent record book. If unmatched initials provide reason to believe that a particular individual may have altered or substituted the specimen, both the proposed and the Final Guidelines provide that the specimen be forwarded for testing along with a second sample obtained as soon as possible after reason to believe the individual may have altered or substituted the specimen is established (2.2(f) (15) and (16)). The Final Guidelines ensure the identification of the person from whom the specimen is collected through the requirement for photo identification (see 2.2(f)(2)). In addition, a principal responsibility of the collection site person is to gather and verify information on site and to detect any problems with the identification of the specimen. Until experience in the program indicates that misidentified samples arising out of unmatched initials is a significant problem, the Guidelines will require that the individual initial the specimen bottle and sign the permanent record book to certify that the identified sample is the one collected from the individual.

21. One commentor asked if the Guidelines apply to Federal contract employees. The Guidelines do not apply to Federal contract employees; however, any agency may require a contractor to test its own employees following the procedures in the Guidelines by making the requirement a term or condition of the contract.

22. One commentor indicated that the proposed requirement for signing a procedure manual on an annual basis was in conflict with current DHHS efforts in the Medicare and CLIA programs to delete the annual signing requirement and replace it with a requirement that the manual be signed initially and whenever changes are made. We concur with the comment that the important factor is that the manual be signed by the responsible individual whenever a procedure is instituted or changed or whenever a new individual becomes responsible for the day-to-day management of the drug testing laboratory. The Guidelines do not require annual signing of the procedure manual.

The on-site review of the laboratory together with the assignment to an individual of the overall responsibility for the testing will assure that the procedures in the manual are current and followed. If the procedures in the manual are not current or followed, it is an indication that the responsible individual is not performing the

oversight function appropriate to the management of the laboratory.

We have also clarified that the individual responsible for the day-to-day management of the drug testing laboratory is the individual responsible for signing the manual (2.3(a)(5)). It is not appropriate for the individual who is responsible for day-to-day operations and supervision of analysts or for any other individual to be delegated this responsibility since the manual is the vehicle for selection of methodologies, and the approval of methodologies is a principal reason for requiring the individual responsible for day-to-day management of the drug testing laboratory to possess detailed knowledge in the area of toxicology.

23. One commentor indicated that laboratories should be notified when they may discard samples. We have reviewed the comment and concur that the agency should be able to notify the laboratory in writing if it determines that samples no longer need to be retained because no further action is pending which will require the samples. Both 2.4(g)(8) and 2.4(h) permit the agency to instruct or authorize storage for less than the period for which there is a storage requirement.

24. Several commentors indicated a discrepancy in the periods for maintenance of frozen samples in storage—1 year in the proposed guidelines and 6 months in Appendix B to the proposed guidelines. The time interval in the appendix was in error. The Final Guidelines consistently call for frozen storage of confirmed positive samples for 1 year (2.4(h)). Note that the Appendix has been omitted, although pertinent provisions from it are integrated in the Final Guidelines.

25. In response to concern that specimens may be misused to test for physiological states other than drug abuse (e.g., pregnancy), a provision has been added to the Final Guidelines to prohibit the specimens collected for urine drug testing from being used for any other types of analyses unless otherwise authorized by law. It is important to the integrity and goals of the President's program to achieve a drug-free work place that any specimens collected for that purpose not be analyzed or used for inappropriate purposes. To ensure that outcome, a paragraph has been added at 2.1(c) stating that specimens may be used only to test for those drugs included in the agency drug-free workplace plan and may not be used to conduct any other analysis or test unless the agency is authorized by law to perform other analyses.

26. One commentator indicated that the individuals permitted in the "secure test area" should include routine service and maintenance personnel and that these individuals should not require escorts. While providing escorts for all employees, including service and maintenance personnel, may cause considerable inconvenience, unless the facilities are secured at night and all materials locked away with no possible access, there is always the potential for tampering with the specimens or test results. The Guidelines make no provision for routine service and maintenance personnel to enter the secure test area without an escort (2.4(a)).

27. One commentator suggested that collection personnel be provided with gloves or other protective garments to prevent contamination of the personnel from the urine. The Department encourages a protected work environment for collection site personnel, including any necessary protective garments. Various State and Federal guidelines provide for the health and safety of employees. Collection agents are expected to be aware of and to comply with such provisions to safeguard their own health and the health and safety of employees. However, no requirement was added to the Guidelines to require provision of protective garments to collection personnel.

28. One commentator recommended that DHHS use its own personnel to investigate any quality assurance problems which arise with a particular laboratory instead of requiring each agency to have its own investigative staff. Other commentators viewed agencies as lacking the in-house expertise to perform this analysis, and it was not clear to them who in each agency should carry out such an investigation. The Final Guidelines reflect a decision that the Secretary (which might include a DHHS contractor or DHHS recognized certification program) shall assume this investigative responsibility and carry out the related coordinating activities. A coordinating mechanism within the National Institute on Drug Abuse (NIDA) will ensure that all agencies are aware of problems with any given laboratory. Conducting investigations and coordinating findings through DHHS will eliminate the need to provide a more complex mechanism for agencies to notify each other about laboratory performance (2.5(d)(4)).

29. Several commentators said that the format for reporting employee drug test results was not sufficiently clear and that while there was a discussion of the

mechanism for reporting performance test results, there was no comparable discussion on reporting employee test results. 2.4(g), Reporting Results, clarifies that laboratories will not report quantitation on test results but will report whether a result is positive or negative and that this is indicative of a result being above or below a particular cutoff limit. A negative report does not signify the absence of a particular drug or metabolite but only that the particular drugs or metabolites screened for were not detected at a specified concentration (i.e., cutoff level).

Quantitation will not be reported to the agency for confirmed positive reports in order to provide for identical reporting by the laboratory of performance test specimens and employee specimens. However, quantitation may be obtained by the Medical Review Officer on request from the laboratory. In the case of the opiates, we have indicated that the particular opiate to be reported will depend on the amounts of morphine and codeine detected by the confirmation test. We have included the reporting scheme in the scientific and technical requirements as well as in the revision of the requirements for reporting performance test results (2.4(g), 3.11 which cross-references 2.4(g), and 3.17(f)).

30. The Final Guidelines attempt to clarify the purpose of the certification program, since the comments reflect uncertainty as to what certification implies and what would be surveyed in the process of certifying a laboratory. Subpart C permits DHHS to recognize certification programs run by other organizations. These programs may be private accrediting organizations that are recognized by the Secretary to determine whether laboratories meet the Guideline requirements. Any laboratory accredited by these organizations in accordance with these Guidelines is deemed to be a certified laboratory, thus making it eligible to perform urine drug testing for Federal agencies. DHHS is contemplating publishing standards for recognition of private accrediting organizations in the near future.

The provisions of Subpart C apply to any laboratory which has or seeks a contract to perform, or otherwise performs urine drug testing for Federal agencies under a drug testing program conducted under E.O. 12564. Only certified laboratories will be authorized to perform urine drug testing for Federal agencies. However, in order to create a pool of qualified laboratories to bid on agency contracts to perform such testing, the Secretary may certify

laboratories as contract eligible that meet the requirements of Subpart C. This pool of qualified laboratories will lead to competitive pricing and better services for Federal agencies.

The certification process will be limited to the five classes of drugs (2.1(a) (1) and (2)) and the methods (2.4 (e) and (f)) specified in these Guidelines. The laboratory will be surveyed and performance tested only for these methods and drugs. Certification of a laboratory indicates that any test result reported by the laboratory for the Federal Government meets the standards in these Guidelines for the five classes of drugs using the methods specified herein. The Guidelines require that a certified laboratory must inform its non-Federal clientele when testing procedures are to be those specified by these Guidelines. Non-Federal purchasers are free to bargain with a certified laboratory for any standards they may deem appropriate.

31. The Guidelines delete the checklist in Appendix B of the proposed certification standards. The checklist was initially intended to provide a tool for the inspectors of laboratories to use in conducting their on-site inspections and to enumerate the standards contained in the section on the certification program published in the *Federal Register*. However, there was confusion regarding whether the checklist represented an additional or different set of requirements. Relevant portions of the checklist have been integrated in the Guidelines. The checklist itself will be revised to correspond to the requirements in the Guidelines and will be made available to laboratories by the DHHS-recognized certification program(s).

32. Several commentators asked that the specific criteria used by the group(s) who will perform the certification function for the Department be detailed in these Guidelines. In response, the Guidelines include a new section explaining how performance testing will be evaluated for initial certification as well as for previously certified laboratories (3.19 (a) and (b)). All major aspects of the certification program, including personnel and quality assurance and quality control requirements, are included in Subpart C of these Guidelines. With the addition of 3.19 (a) and (b), we believe the Guidelines are appropriately specific and there is no need to include additional detail in the Guidelines concerning the certification process.

33. Some commentators indicated that the number of blind performance test samples required to be run by the

laboratories (i.e., 1,000) for initial certification and (i.e., 250 per quarter) for continuing certification was excessive and would be too costly. The commentors also indicated that it was not clear whether the laboratory or the submitting organization would bear the cost of the samples and if it were necessary for each submitting organization to submit this number of samples to each laboratory. In response to the comments, we have revised this section to indicate that each agency shall submit blind performance test specimens to each laboratory it contracts with in the amount of at least 50 percent of the total number of samples submitted (up to a maximum of 500 samples) during the initial 90-day period of program implementation and a minimum of 10 percent of all samples (to a maximum of 250) submitted per quarter thereafter. The Final Guidelines also clarify that approximately 80 percent of the blind performance test samples are to be blank (i.e., certified to be drug free) and the remaining samples are to be positives (2.52(d)(3) and 3.7). The cost of the blind performance test samples will be borne by the submitting agency.

34. Several commentors requested corrective action and reanalysis of previously run specimens in the case of discovered laboratory administrative error. They also requested that the union and all employees who tested positive be notified of the error in writing. The recommendation was to notify all employees with positive results who were tested between the time of resolution of the error and the preceding cycle of correct results. In the case of an administrative error, there are no plans to automatically have all specimens retested. The decision on whether to retest will be dependent on the type and extent of the error. For example, if a single employee's test results were transcribed incorrectly, nothing would be gained from rerunning all the specimens in a given timeframe since it would not change the values attributed to the specimens. If an error occurred such that it was not clear whose specimen was being tested and which results belonged to which specimen, this would require retesting of the group for which the values were uncertain and for those analytes for which the values were uncertain. However, it would be unproductive to require the automatic retesting of all specimens for any error.

Agency policy under which individuals are notified of errors will depend on the circumstances. If the error is corrected before the results are reported to any employee, it is

unnecessary to notify each employee that an error was discovered and subsequently corrected. If a discovered error affects an employee after results have been reported, the Medical Review Officer will be notified and the affected employee will also be notified through the appropriate mechanisms established by each agency.

35. Several commentors indicated that the laboratory contract should be suspended if the laboratory committed the same administrative error twice and that the designated reviewing official's discretion to continue a laboratory in the program should be more limited or more clearly defined. The Department has reviewed the comments concerning the point at which a contract should be suspended because of an administrative error and submits that the current policy allows sufficient flexibility and protection to the employee and the laboratory and that it should not be changed. There are no circumstances under which administrative or human error can be entirely eliminated. The major assurance of accuracy in the overall program is the series of checks to assure that such errors are detected and corrected. The reviewing official has been given the necessary flexibility and definition of authority to make the appropriate technical and program judgments concerning the status of each facility and to assure that reasonable and responsible decisions are made. Nevertheless, the Final Guidelines add several features to put greater responsibility on the individual responsible for the day-to-day management of the drug testing laboratory for the quality assurance program and ensuring that quality assurance procedures are followed. These Guidelines also more clearly describe what constitutes a quality assurance and quality control program to detect and correct errors (2.5) and a program of performance testing (3.17-3.19).

We have chosen not to include a formal definition of administrative or clerical error in the Guidelines as was suggested. Among the errors to which either term refers are incorrect transcription of test results or errors in recording specimen identities, i.e., errors that are not due to the analysis of the specimens with regard to analytical accuracy, precision, interpretation of test results, or calibration of equipment. Clearly analytical errors are not considered "administrative." While it is not possible to write guidelines that cover every possibility, at no place in these Guidelines are incorrect analyses considered administrative error but

rather are consistently treated as a basis for prompt action against the laboratory by the responsible officials.

36. Several commentors indicated that laboratory inspections should be conducted unannounced and that union representatives should be permitted to accompany the inspection teams. The Guidelines neither require nor prohibit unannounced inspections. They contemplate that agencies will, through their contract with a certified laboratory, specify the terms and conditions of inspections in accordance with the requirements in the Guidelines. If individuals other than members of the inspection team were entitled to accompany the inspectors, it would significantly complicate coordination and conduct of the inspections. More importantly, we see additional participants in the inspection as inhibiting the laboratory's freedom to provide complete cooperation out of concern for protecting proprietary information. While some laboratories may be willing to provide escorted tours to union officials to illustrate the quality of their processes, the Guidelines do not establish a right for union officials to participate in inspections incident to certification of laboratories under these Guidelines (2.4(1) and 3.20).

37. One commentor indicated that any of the five general factors indicated in 3.13(b) as a possible basis for revocation in the certification requirements should inevitably lead to revocation without any further determination that the revocation is "necessary." The issue of how many potential grounds for revocation are necessary to determine that revocation of a laboratory is necessary was considered when the list of grounds was developed. The Department views the nature and seriousness of the facts concerning the grounds for revocation as factors to be weighed in deciding to revoke a certification. It is difficult and would not contribute to the maintenance of high quality testing standards to develop *a priori* statements about the magnitude of an offense or a combination of violations and to formulate necessary actions in response to each possible violation of the provisions of 3.13. All five factors listed are considered serious violations of these certification criteria, and it is not necessary for more than one factor to be violated to take action against a laboratory. However, the Guidelines retain the flexibility for the Secretary to determine that revocation is necessary to ensure the full reliability and accuracy of drug tests and the accurate reporting of test results (3.13(b)).

38. Several commentors indicated that when a laboratory fails a performance test it would be inordinately expensive (especially in high volume laboratories) to retest all samples since the last performance test the laboratory passed and to test for all analytes rather than for the one analyte for which the laboratory had failed performance testing. The reason for retesting all positive samples since the last successful performance test is that the quality of the test results has been called into question. In order to verify test results for the period between a successful performance testing and the failed testing, it will be necessary to retest all specimens tested positive for which an incorrect analysis may have been performed. It is not routinely necessary to retest for all analytes but only for those on which the laboratory failed its performance testing. However, the laboratory may be required to test for other analytes if the performance test failure reflects broader problems (3.19(b)(1)(v)).

39. Several commentors indicated that performance testing every other month is excessive and that quarterly testing would be sufficient to assure the quality of the testing. Others indicated that fewer challenges per shipment would be adequate to determine the quality of the laboratory. Still other individuals stated that the limits for acceptable performance on performance tests were too high in terms of the concentrations used. Others said that the grading criterion of failure based on one false positive was too strict. We have reviewed the concerns that bimonthly performance testing is excessive and maintain that the use of performance tests is a valid outcome measure of performance and will assist in the evaluation of quality of the laboratory performance. If future experience with the program indicates that a lesser frequency will assure the quality of the testing, we will revise the frequency and the number of specimens accordingly. Relatively frequent performance testing reduces the time period for which samples may have to be rerun in case of performance test failure (3.17).

To the extent that the Guidelines amended the cutoff limits for drugs for which employees may be tested for consistency with those currently used by the Department of Defense, it was necessary to modify the values of the various performance test samples correspondingly. We have clarified that a laboratory must achieve an overall grade of 90 percent on the first three cumulative shipments of performance tests and that if such a poor grade is

obtained on the first or second challenge that a laboratory cannot achieve an overall grade of 90 percent on the three successive performance test challenges, then the laboratory will fail at that point. Laboratories already in the program must achieve a grade of 90 percent on each shipment of performance testing. It was unclear in the proposed notice whether the grade of 90 percent referred only to the positive samples. We intend that the 90 percent refer only to positive samples, since any negative sample giving rise to a false positive would be the basis for automatic disqualification for initial certification. It also was unclear whether the 90 percent referred to performance on all drugs in the shipment, not on each drug tested. We have clarified the Guidelines in both these areas. We adopted a strategy requiring 90 percent for all drugs because it is not always feasible to have a sufficient number of challenges for each drug in each shipment to avoid a single failure on a drug leading to a failing grade of less than 90 percent (3.19(b)(2)).

40. Some commentors thought laboratories should be required to notify all users if their certification was revoked. Since the requirements in these Guidelines only apply to certification for Federal drug testing programs, it would be inappropriate to require laboratories to notify non-Federal users of revocation or suspension.

41. We have not adopted the recommendations that any changes in the Guidelines be accomplished by publication of a notice, review of comments, and then publication of final changes. (Section 503 of Pub. L. 100-71 required such steps for initial development of these Guidelines.) The time required for this process would not permit rapid adjustment to changes in technology. Accordingly, the Guidelines retain the provision permitting final revision of these Guidelines by publication of a notice in the *Federal Register* (1.3).

42. One commentor suggested that only positive tests be certified as to accuracy and validity before reporting. Although this practice would reduce paperwork, it does not reflect the potential impact on public safety of false negative results. The Guidelines continue to require that negative results be reviewed carefully and attested to by the proper officials in the same way as positive results (2.4(g)).

43. One commentor wanted us to specify the time the individual responsible for day-to-day management must spend in the laboratory. No change

has been made in the Guidelines. The critical factor here is the quality of the work and not the absolute number of hours spent. The Department views the use of outcome measures of performance for the laboratory as more effective in assuring accurate and reliable test results than attempting to set hours for the responsible individual particularly in view of the qualifications which the Guidelines set for the individual responsible for day-to-day management of the drug testing laboratory.

44. The criterion for retesting specimens (i.e., those being challenged) was clarified to indicate that in performing a retest the laboratory must confirm the presence of the substance but does not have to confirm that it is present above the cutoff level. Since the drug levels may deteriorate with time, it is only necessary to show that the drug (or its metabolite) is present to reconfirm its presence during retesting (2.4(i)).

45. A provision has been added to the Guidelines requiring that laboratories be capable of testing for at least the five classes of drugs specified in the Guidelines. The laboratories are being required to possess the flexibility to test for all the specified classes of drugs in order to assure that they have a sufficient range of capabilities to respond to the agencies' testing protocols, including testing for reasonable suspicion (3.4).

46. Several Federal agencies commenting on the proposed guidelines sought waivers of particular provisions in reliance on the original Scientific and Technical Guidelines issued February 13, 1987, which provided that, "Agencies may not deviate from the provisions of these Guidelines without the written approval of the Secretary, Health and Human Services or his designee." This waiver statement, which was not explicit in the proposed guidelines, is included at 1.1(f). Absent such a waiver, these Guidelines represent the exclusive standard for urinalysis testing and agencies may not deviate from these established procedures.

In order to clarify that the laboratory certification standards apply to laboratories which have or seek certification to perform urine drug testing for Federal agencies, a paragraph was added to the applicability section, 1.1(c), stating that Subpart C of the Guidelines applies to any laboratory which has or seeks such certification and that certification is required to perform urine drug testing for Federal agencies.

Section 4(d) of E.O. 12564 states that "agencies shall conduct their drug testing programs in accordance with * * * [scientific and technical] guidelines" promulgated by the Secretary of Health and Human Services. Since the Guidelines impose mandatory requirements on a Government-wide basis, they are exempt from the duty to bargain under section 7117(a)(1) of the Federal Service Labor-Management Relations Statute.

Information Collection Requirements

Information collection and recordkeeping requirements which would be imposed on laboratories engaged in urine drug testing for Federal agencies concern quality assurance and quality control; security and chain of custody; documentation; reports; performance testing; and inspections as set out in 3.7, 3.8, 3.10, 3.11, 3.17, and 3.20. To facilitate ease of use and uniform reporting, standard forms have been developed for chain of custody records and the permanent record books as referenced in 2.2(c) and (f).

The information collection and recordkeeping requirements contained in these Final Guidelines have been approved by the Office of Management and Budget under section 3504(h) of the Paperwork Reduction Act of 1980 and have been assigned control number 09300130, approved through April 30, 1989.

Date: April 1, 1988.

Robert E. Windom,
Assistant Secretary for Health.

Date: April 1, 1988.

Otis R. Bowen,
Secretary.

These Final Mandatory Guidelines are hereby adopted in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71 as set forth below:

MANDATORY GUIDELINES FOR FEDERAL WORKPLACE DRUG TESTING PROGRAMS

Subpart A—General

- 1.1 Applicability.
- 1.2 Definitions.
- 1.3 Future Revisions.

Subpart B—Scientific and Technical Requirements

- 2.1 The Drugs.
- 2.2 Specimen Collection Procedures.
- 2.3 Laboratory Personnel.
- 2.4 Laboratory Analysis Procedures.
- 2.5 Quality Assurance and Quality Control.
- 2.6 Interim Certification Procedures.
- 2.7 Reporting and Review of Results.
- 2.8 Protection of Employee Records.
- 2.9 Individual Access to Test and Laboratory Certification Results.

Subpart C—Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies

- 3.1 Introduction.
- 3.2 Goals and Objectives of Certification.
- 3.3 General Certification Requirements.
- 3.4 Capability to Test for Five Classes of Drugs.
- 3.5 Initial and Confirmatory Capability at Same Site.
- 3.6 Personnel.
- 3.7 Quality Assurance and Quality Control.
- 3.8 Security and Chain of Custody.
- 3.9 One-Year Storage for Confirmed Positives.
- 3.10 Documentation.
- 3.11 Reports.
- 3.12 Certification.
- 3.13 Revocation.
- 3.14 Suspension.
- 3.15 Notice; Opportunity for Review.
- 3.16 Recertification.
- 3.17 Performance Test Requirement for Certification.
- 3.18 Performance Test Specimen Composition.
- 3.19 Evaluation of Performance Testing.
- 3.20 Inspections.
- 3.21 Results of Inadequate Performance.

Authority: E.O. 12564 and sec. 503 of Pub. L. 100-71.

Subpart A—General

1.1 Applicability.

(a) These mandatory guidelines apply to:

(1) Executive Agencies as defined in 5 U.S.C. 105;

(2) The Uniformed Services, as defined in 5 U.S.C. 2101 (3) (but excluding the Armed Forces as defined in 5 U.S.C. 2101(2));

(3) And any other employing unit or authority of the Federal Government except the United States Postal Service, the Postal Rate Commission, and employing units or authorities in the Judicial and Legislative Branches.

(b) Any agency or component of an agency with a drug testing program in existence as of September 15, 1986, and the Departments of Transportation and Energy shall take such action as may be necessary to ensure that the agency is brought into compliance with these Guidelines no later than 90 days after they take effect, except that any judicial challenge that affects these Guidelines shall not affect drug testing programs subject to this paragraph.

(c) Except as provided in 2.6, Subpart C of these Guidelines (which establishes laboratory certification standards) applies to any laboratory which has or seeks certification to perform urine drug testing for Federal agencies under a drug testing program conducted under E.O. 12564. Only laboratories certified under these standards are authorized to perform urine drug testing for Federal agencies.

(d) The Intelligence Community, as defined by Executive Order No. 12333, shall be subject to these Guidelines only to the extent agreed to by the head of the affected agency.

(e) These Guidelines do not apply to drug testing conducted under legal authority other than E.O. 12564, including testing of persons in the criminal justice system, such as arrestees, detainees, probationers, incarcerated persons, or parolees.

(f) Agencies may not deviate from the provisions of these Guidelines without the written approval of the Secretary. In requesting approval for a deviation, an agency must petition the Secretary in writing and describe the specific provision or provisions for which a deviation is sought and the rationale therefor. The Secretary may approve the request upon a finding of good cause as determined by the Secretary.

1.2 Definitions.

For purposes of these Guidelines the following definitions are adopted:

Aliquot A portion of a specimen used for testing.

Chain of Custody Procedures to account for the integrity of each urine specimen by tracking its handling and storage from point of specimen collection to final disposition of the specimen. These procedures shall require that an approved agency chain of custody form be used from time of collection to receipt by the laboratory and that upon receipt of the laboratory an appropriate laboratory chain of custody form(s) account for the sample or sample aliquots within the laboratory. Chain of custody forms shall, at a minimum, include an entry documenting date and purpose each time a specimen or aliquot is handled or transferred and identifying every individual in the chain of custody.

Collection Site A place designated by the agency where individuals present themselves for the purpose of providing a specimen of their urine to be analyzed for the presence of drugs.

Collection Site Person A person who instructs and assists individuals at a collection site and who receives and makes an initial examination of the urine specimen provided by those individuals. A collection site person shall have successfully completed training to carry out this function.

Confirmatory Test A second analytical procedure to identify the presence of a specific drug or metabolite which is independent of the initial test and which uses a different technique and chemical principle from that of the initial test in order to ensure reliability

and accuracy. (At this time gas chromatography/mass spectrometry (GC/MS) is the only authorized confirmation method for cocaine, marijuana, opiates, amphetamines, and phencyclidine.)

Initial Test (also known as Screening Test) An immunosay screen to eliminate "negative" urine specimens from further consideration.

Medical Review Officer A licensed physician responsible for receiving laboratory results generated by an agency's drug testing program who has knowledge of substance abuse disorders and has appropriate medical training to interpret and evaluate an individual's positive test result together with his or her medical history and any other relevant biomedical information.

Permanent Record Book A permanently bound book in which identifying data on each specimen collected at a collection site are permanently recorded in the sequence of collection.

Reason to Believe Reason to believe that a particular individual may alter or substitute the urine specimen as provided in section 4(c) of E.O. 12564.

Secretary The Secretary of Health and Human Services or the Secretary's designee. The Secretary's designee may be contractor or other recognized organization which acts on behalf of the Secretary in implementing these Guidelines.

1.3 Future Revisions.

In order to ensure the full reliability and accuracy of drug assays, the accurate reporting of test results, and the integrity and efficacy of Federal drug testing programs, the Secretary may make changes to these Guidelines to reflect improvements in the available science and technology. These changes will be published in final as a notice in the Federal Register.

Subpart B—Scientific and Technical Requirements

2.1 The Drugs.

(a) The President's Executive Order 12564 defines "illegal drugs" as those included in Schedule I or II of the Controlled Substances Act (CSA), but not when used pursuant to a valid prescription or when used as otherwise authorized by law. Hundreds of drugs are covered under Schedule I and II and while it is not feasible to test routinely for all of them, Federal drug testing programs shall test for drugs as follows:

(1) Federal agency applicant and random drug testing programs shall at a minimum test for marijuana and cocaine;

(2) Federal agency applicant and random drug testing programs are also authorized to test for opiates, amphetamines, and phencyclidine; and

(3) When conducting reasonable suspicion, accident, or unsafe practice testing, a Federal agency may test for any drug listed in Schedule I or II of the CSA.

(b) Any agency covered by these guidelines shall petition the Secretary in writing for approval to include in its testing protocols any drugs (or classes of drugs) not listed for Federal agency testing in paragraph (a) of this section. Such approval shall be limited to the use of the appropriate science and technology and shall not otherwise limit agency discretion to test for any drugs covered under Schedule I or II of the CSA.

(c) Urine specimens collected pursuant to Executive Order 12564, Pub. L. 100-71, and these Guidelines shall be used only to test for those drugs included in agency drug-free workplace plans and may not be used to conduct any other analysis or test unless otherwise authorized by law.

(d) These Guidelines are not intended to limit any agency which is specifically authorized by law to include additional categories of drugs in the drug testing of its own employees or employees in its regulated industries.

2.2 Specimen Collection Procedures.

(a) **Designation of Collection Site.** Each agency drug testing program shall have one or more designated collection sites which have all necessary personnel, materials, equipment, facilities, and supervision to provide for the collection, security, temporary storage, and shipping or transportation of urine specimens to a certified drug testing laboratory.

(b) **Security Procedures** shall provide for the designated collection site to be secure. If a collection site facility is dedicated solely to urine collection, it shall be secure at all times. If a facility cannot be dedicated solely to drug testing, the portion of the facility used for testing shall be secured during drug testing.

(c) **Chain of Custody.** Chain of custody standardized forms shall be properly executed by authorized collection site personnel upon receipt of specimens. Handling and transportation of urine specimens from one authorized individual or place to another shall always be accomplished through chain of custody procedures. Every effort shall be made to minimize the number of persons handling specimens.

(d) **Access to Authorized Personnel Only.** No unauthorized personnel shall

be permitted in any part of the designated collection site when urine specimens are collected or stored.

(e) **Privacy.** Procedures for collecting urine specimens shall allow individual privacy unless there is reason to believe that a particular individual may alter or substitute the specimen to be provided.

(f) **Integrity and Identity of Specimen.** Agencies shall take precautions to ensure that a urine specimen not be adulterated or diluted during the collection procedure and that information on the urine bottle and in the record book can identify the individual from whom the specimen was collected. The following minimum precautions shall be taken to ensure that unadulterated specimens are obtained and correctly identified:

(1) To deter the dilution of specimens at the collection site, toilet bluing agents shall be placed in toilet tanks wherever possible, so the reservoir of water in the toilet bowl always remains blue. There shall be no other source of water (e.g., no shower or sink) in the enclosure where urination occurs.

(2) When an individual arrives at the collection site, the collection site person shall request the individual to present photo identification. If the individual does not have proper photo identification, the collection site person shall contact the supervisor of the individual, the coordinator of the drug testing program, or any other agency official who can positively identify the individual. If the individual's identity cannot be established, the collection site person shall not proceed with the collection.

(3) If the individual fails to arrive at the assigned time, the collection site person shall contact the appropriate authority to obtain guidance on the action to be taken.

(4) The collection site person shall ask the individual to remove any unnecessary outer garments such as a coat or jacket that might conceal items or substances that could be used to tamper with or adulterate the individual's urine specimen. The collection site person shall ensure that all personal belongings such as a purse or briefcase remain with the outer garments. The individual may retain his or her wallet.

(5) The individual shall be instructed to wash and dry his or her hands prior to urination.

(6) After washing hands, the individual shall remain in the presence of the collection site person and shall not have access to any water fountain, faucet, soap dispenser, cleaning agent or

any other materials which could be used to adulterate the specimen.

(7) The individual may provide his/her specimen in the privacy of a stall or otherwise partitioned area that allows for individual privacy.

(8) The collection site person shall note any unusual behavior or appearance in the permanent record book.

(9) In the exceptional event that an agency-designated collection site is not accessible and there is an immediate requirement for specimen collection (e.g., an accident investigation), a public rest room may be used according to the following procedures: A collection site person of the same gender as the individual shall accompany the individual into the public rest room which shall be made secure during the collection procedure. If possible, a toilet bluing agent shall be placed in the bowl and any accessible toilet tank. The collection site person shall remain in the rest room, but outside the stall, until the specimen is collected. If no bluing agent is available to deter specimen dilution, the collection site person shall instruct the individual not to flush the toilet until the specimen is delivered to the collection site person. After the collection site person has possession of the specimen, the individual will be instructed to flush the toilet and to participate with the collection site person in completing the chain of custody procedures.

(10) Upon receiving the specimen from the individual, the collection site person shall determine that it contains at least 60 milliliters of urine. If there is less than 60 milliliters of urine in the container, additional urine shall be collected in a separate container to reach a total of 60 milliliters. (The temperature of the partial specimen in each separate container shall be measured in accordance with paragraph (f)(12) of this section, and the partial specimens shall be combined in one container.) The individual may be given a reasonable amount of liquid to drink for this purpose (e.g., a glass of water). If the individual fails for any reason to provide 60 milliliters of urine, the collection site person shall contact the appropriate authority to obtain guidance on the action to be taken.

(11) After the specimen has been provided and submitted to the collection site person, the individual shall be allowed to wash his or her hands.

(12) Immediately after the specimen is collected, the collection site person shall measure the temperature of the specimen. The temperature measuring device used must accurately reflect the temperature of the specimen and not

contaminate the specimen. The time from urination to temperature measurement is critical and in no case shall exceed 4 minutes.

(13) If the temperature of a specimen is outside the range of 32.5°–37.7°C/90.5°–99.8°F, that is a reason to believe that the individual may have altered or substituted the specimen, and another specimen shall be collected under direct observation of a same gender collection site person and both specimens shall be forwarded to the laboratory for testing. An individual may volunteer to have his or her oral temperature taken to provide evidence to counter the reason to believe the individual may have altered or substituted the specimen caused by the specimen's temperature falling outside the prescribed range.

(14) Immediately after the specimen is collected, the collection site person shall also inspect the specimen to determine its color and look for any signs of contaminants. Any unusual findings shall be noted in the permanent record book.

(15) All specimens suspected of being adulterated shall be forwarded to the laboratory for testing.

(16) Whenever there is reason to believe that a particular individual may alter or substitute the specimen to be provided, a second specimen shall be obtained as soon as possible under the direct observation of a same gender collection site person.

(17) Both the individual being tested and the collection site person shall keep the specimen in view at all times prior to its being sealed and labeled. If the specimen is transferred to a second bottle, the collection site person shall request the individual to observe the transfer of the specimen and the placement of the tamperproof seal over the bottle cap and down the sides of the bottle.

(18) The collection site person and the individual shall be present at the same time during procedures outlined in paragraphs (f)(19)–(f)(22) of this section.

(19) The collection site person shall place securely on the bottle an identification label which contains the date, the individual's specimen number, and any other identifying information provided or required by the agency.

(20) The individual shall initial the identification label on the specimen bottle for the purpose of certifying that it is the specimen collected from him or her.

(21) The collection site person shall enter in the permanent record book all information identifying the specimen. The collection site person shall sign the permanent record book next to the identifying information.

(22) The individual shall be asked to read and sign a statement in the permanent record book certifying that the specimen identified as having been collected from him or her is in fact that specimen he or she provided.

(23) A higher level supervisor shall review and concur in advance with any decision by a collection site person to obtain a specimen under the direct observation of a same gender collection site person based on a reason to believe that the individual may alter or substitute the specimen to be provided.

(24) The collection site person shall complete the chain of custody form.

(25) The urine specimen and chain of custody form are now ready for shipment. If the specimen is not immediately prepared for shipment, it shall be appropriately safeguarded during temporary storage.

(26) While any part of the above chain of custody procedures is being performed, it is essential that the urine specimen and custody documents be under the control of the involved collection site person. If the involved collection site person leaves his or her work station momentarily, the specimen and custody form shall be taken with him or her or shall be secured. After the collection site person returns to the work station, the custody process will continue. If the collection site person is leaving for an extended period of time, the specimen shall be packaged for mailing before he or she leaves the site.

(g) *Collection Control.* To the maximum extent possible, collection site personnel shall keep the individual's specimen bottle within sight both before and after the individual has urinated. After the specimen is collected, it shall be properly sealed and labeled. An approved chain of custody form shall be used for maintaining control and accountability of each specimen from the point of collection to final disposition of the specimen. The date and purpose shall be documented on an approved chain of custody form each time a specimen is handled or transferred and every individual in the chain shall be identified. Every effort shall be made to minimize the number of persons handling specimens.

(h) *Transportation to Laboratory.* Collection site personnel shall arrange to ship the collected specimens to the drug testing laboratory. The specimens shall be placed in containers designed to minimize the possibility of damage during shipment, for example, specimen boxes or padded mailers; and those containers shall be securely sealed to eliminate the possibility of undetected tampering. On the tape sealing the

container, the collection site supervisor shall sign and enter the date specimens were sealed in the containers for shipment. The collection site personnel shall ensure that the chain of custody documentation is attached to each container sealed for shipment to the drug testing laboratory.

2.3 Laboratory Personnel.

(a) Day-to-Day Management.

(1) The laboratory shall have a qualified individual to assume professional, organizational, educational, and administrative responsibility for the laboratory's urine drug testing facility.

(2) This individual shall have documented scientific qualifications in analytical forensic toxicology. Minimum qualifications are:

(i) Certification as a laboratory director by the State in forensic or clinical laboratory toxicology; or

(ii) A Ph.D. in one of the natural sciences with an adequate undergraduate and graduate education in biology, chemistry, and pharmacology or toxicology, or

(iii) Training and experience comparable to a Ph.D. in one of the natural sciences, such as a medical or scientific degree with additional training and laboratory/research experience in biology, chemistry, and pharmacology or toxicology; and

(iv) In addition to the requirements in (i), (ii), and (iii) above, minimum qualifications also require:

(A) Appropriate experience in analytical forensic toxicology including experience with the analysis of biological material for drugs of abuse, and

(B) Appropriate training and/or experience in forensic applications of analytical toxicology, e.g., publications, court testimony, research concerning analytical toxicology of drugs of abuse, or other factors which qualify the individual as an expert witness in forensic toxicology.

(3) This individual shall be engaged in and responsible for the day-to-day management of the drug testing laboratory even where another individual has overall responsibility for an entire multispecialty laboratory.

(4) This individual shall be responsible for ensuring that there are enough personnel with adequate training and experience to supervise and conduct the work of the drug testing laboratory. He or she shall assure the continued competency of laboratory personnel by documenting their inservice training, reviewing their work performance, and verifying their skills.

(5) This individual shall be responsible for the laboratory's having a procedure manual which is complete, up-to-date, available for personnel performing tests, and followed by those personnel. The procedure manual shall be reviewed, signed, and dated by this responsible individual whenever procedures are first placed into use or changed or when a new individual assumes responsibility for management of the drug testing laboratory. Copies of all procedures and dates on which they are in effect shall be maintained. (Specific contents of the procedure manual are described in 2.4(n)(1).)

(6) This individual shall be responsible for maintaining a quality assurance program to assure the proper performance and reporting of all test results; for maintaining acceptable analytical performance for all controls and standards; for maintaining quality control testing; and for assuring and documenting the validity, reliability, accuracy, precision, and performance characteristics of each test and test system.

(7) This individual shall be responsible for taking all remedial actions necessary to maintain satisfactory operation and performance of the laboratory in response to quality control systems not being within performance specifications, errors in result reporting or in analysis of performance testing results. This individual shall ensure that sample results are not reported until all corrective actions have been taken and he or she can assure that the tests results provided are accurate and reliable.

(b) *Test Validation.* The laboratory's urine drug testing facility shall have a qualified individual(s) who reviews all pertinent data and quality control results in order to attest to the validity of the laboratory's test reports. A laboratory may designate more than one person to perform this function. This individual(s) may be any employee who is qualified to be responsible for day-to-day management or operation of the drug testing laboratory.

(c) *Day-to-Day Operations and Supervision of Analysts.* The laboratory's urine drug testing facility shall have an individual to be responsible for day-to-day operations and to supervise the technical analysts. This individual(s) shall have at least a bachelor's degree in the chemical or biological sciences or medical technology or equivalent. He or she shall have training and experience in the theory and practice of the procedures used in the laboratory, resulting in his or her thorough understanding of quality

control practices and procedures; the review, interpretation, and reporting of test results; maintenance of chain of custody; and proper remedial actions to be taken in response to test systems being out of control limits or detecting aberrant test or quality control results.

(d) *Other Personnel.* Other technicians or nontechnical staff shall have the necessary training and skills for the tasks assigned.

(e) *Training.* The laboratory's urine drug testing program shall make available continuing education programs to meet the needs of laboratory personnel.

(f) *Files.* Laboratory personnel files shall include: resume of training and experience; certification or license, if any; references; job descriptions; records of performance evaluation and advancement; incident reports; and results of tests which establish employee competency for the position he or she holds, such as a test for color blindness, if appropriate.

2.4 Laboratory Analysis Procedures.

(a) *Security and Chain of Custody.* (1) Drug testing laboratories shall be secure at all times. They shall have in place sufficient security measures to control access to the premises and to ensure that no unauthorized personnel handle specimens or gain access to the laboratory processes or to areas where records are stored. Access to these secured areas shall be limited to specifically authorized individuals whose authorization is documented. With the exception of personnel authorized to conduct inspections on behalf of Federal agencies for which the laboratory is engaged in urine testing or on behalf of the Secretary, all authorized visitors and maintenance and service personnel shall be escorted at all times. Documentation of individuals accessing these areas, dates, and time of entry and purpose of entry must be maintained.

(2) Laboratories shall use chain of custody procedures to maintain control and accountability of specimens from receipt through completion of testing, reporting of results, during storage, and continuing until final disposition of specimens. The date and purpose shall be documented on an appropriate chain of custody form each time a specimen is handled or transferred, and every individual in the chain shall be identified. Accordingly, authorized technicians shall be responsible for each urine specimen or aliquot in their possession and shall sign and complete chain of custody forms for those specimens or aliquots as they are received.

(b) *Receiving.* (1) When a shipment of specimens is received, laboratory personnel shall inspect each package for evidence of possible tampering and compare information on specimen bottles within each package to the information on the accompanying chain of custody forms. Any direct evidence of tampering or discrepancies in the information on specimen bottles and the agency's chain of custody forms attached to the shipment shall be immediately reported to the agency and shall be noted on the laboratory's chain of custody form which shall accompany the specimens while they are in the laboratory's possession.

(2) Specimen bottles will normally be retained within the laboratory's accession area until all analyses have been completed. Aliquots and the laboratory's chain of custody forms shall be used by laboratory personnel for conducting initial and confirmatory tests.

(c) *Short-Term Refrigerated Storage.* Specimens that do not receive an initial test within 7 days of arrival at the laboratory shall be placed in secure refrigeration units. Temperatures shall not exceed 6°C. Emergency power equipment shall be available in case of prolonged power failure.

(d) *Specimen Processing.* Laboratory facilities for urine drug testing will normally process specimens by grouping them into batches. The number of specimens in each batch may vary significantly depending on the size of the laboratory and its workload. When conducting either initial or confirmatory tests, every batch shall contain an appropriate number of standards for calibrating the instrumentation and a minimum of 10 percent controls. Both quality control and blind performance test samples shall appear as ordinary samples to laboratory analysts.

(e) *Initial Test.* (1) The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether they are negative for these five drugs or classes of drugs:

	Initial test level (ng/ml)
Marijuana metabolites.....	100
Cocaine metabolites.....	300
Opiate metabolites.....	* 300
Phencyclidine.....	25
Amphetamines.....	1,000

* 25ng/ml if immunoassay specific for free morphine.

(2) These test levels are subject to change by the Department of Health and Human Services as advances in technology or other considerations warrant identification of these substances at other concentrations. Initial test methods and testing levels for other drugs shall be submitted in writing by the agency for the written approval of the Secretary.

(f) *Confirmatory Test.* (1) All specimens identified as positive on the initial test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques at the cutoff values listed in this paragraph for each drug. All confirmations shall be by quantitative analysis. Concentrations which exceed the linear region of the standard curve shall be documented in the laboratory record as "greater than highest standard curve value."

	Confirma- tory test level (ng/ ml)
Marijuana metabolite ¹	15
Cocaine metabolite ²	150
Opiates:	
Morphine.....	* 300
Codeine.....	* 300
Phencyclidine.....	25
Amphetamines:	
Amphetamine.....	500
Methamphetamine.....	500

¹ Delta-9-tetrahydrocannabinol-9-carboxylic acid.
² Benzoylcegonine.

(2) These test levels are subject to change by the Department of Health and Human Services as advances in technology or other considerations warrant identification of these substances at other concentrations. Confirmatory test methods and testing levels for other drugs shall be submitted in writing by the agency for the written approval of the Secretary.

(g) *Reporting Results.* (1) The laboratory shall report test results to the agency's Medical Review Officer within an average of 5 working days after receipt of the specimen by the laboratory. Before any test result is reported (the results of initial tests, confirmatory tests, or quality control data), it shall be reviewed and the test certified as an accurate report by the responsible individual. The report shall identify the drugs/metabolites tested for, whether positive or negative, and the cutoff for each, the specimen number assigned by the agency, and the drug testing laboratory specimen identification number. The results (positive and negative) for all specimens submitted at the same time to the laboratory shall be reported back to the Medical Review Officer at the same time.

(2) The laboratory shall report as negative all specimens which are negative on the initial test or negative on the confirmatory test. Only specimens confirmed positive shall be reported positive for a specific drug.

(3) The Medical Review Officer may request from the laboratory and the laboratory shall provide quantitation of test results. The Medical Review Officer may not disclose quantitation of test results to the agency but shall report only whether the test was positive or negative.

(4) The laboratory may transmit results to the Medical Review Officer by various electronic means (for example, teleprinters, facsimile, or computer) in a manner designed to ensure confidentiality of the information. Results may not be provided verbally by telephone. The laboratory must ensure the security of the data transmission and limit access to any data transmission, storage, and retrieval system.

(5) The laboratory shall send only to the Medical Review Officer a certified copy of the original chain of custody form signed by the individual responsible for day-to-day management of the drug testing laboratory or the individual responsible for attesting to the validity of the test reports.

(6) The laboratory shall provide to the agency official responsible for coordination of the drug-free workplace program a monthly statistical summary of urinalysis testing of Federal employees and shall not include in the summary any personal identifying information. Initial and confirmation data shall be included from test results reported within that month. Normally this summary shall be forwarded by registered or certified mail not more than 14 calendar days after the end of the month covered by the summary. The summary shall contain the following information:

(i) Initial Testing:

- (A) Number of specimens received;
- (B) Number of specimens reported out;

and
(C) Number of specimens screened positive for:

- Marijuana metabolites
- Cocaine metabolites
- Opiate metabolites
- Phencyclidine
- Amphetamines

(ii) Confirmatory Testing:

- (A) Number of specimens received for confirmation;

(B) Number of specimens confirmed positive for:

- Marijuana metabolite

Cocaine metabolite
Morphine, codeine
Phencyclidine
Amphetamine
Methamphetamine

(7) The laboratory shall make available copies of all analytical results for Federal drug testing programs when requested by DHHS or any Federal agency for which the laboratory is performing drug testing services.

(8) Unless otherwise instructed by the agency in writing, all records pertaining to a given urine specimen shall be retained by the drug testing laboratory for a minimum of 2 years.

(h) *Long-Term Storage.* Long-term frozen storage (-20°C or less) ensures that positive urine specimens will be available for any necessary retest during administrative or disciplinary proceedings. Unless otherwise authorized in writing by the agency, drug testing laboratories shall retain and place in properly secured long-term frozen storage for a minimum of 1 year all specimens confirmed positive. Within this 1-year period an agency may request the laboratory to retain the specimen for an additional period of time, but if no such request is received the laboratory may discard the specimen after the end of 1 year, except that the laboratory shall be required to maintain any specimens under legal challenge for an indefinite period.

(i) *Retesting Specimens.* Because some analytes deteriorate or are lost during freezing and/or storage, quantitation for a retest is not subject to a specific cutoff requirement but must provide data sufficient to confirm the presence of the drug or metabolite.

(j) *Subcontracting.* Drug testing laboratories shall not subcontract and shall perform all work with their own personnel and equipment unless otherwise authorized by the agency. The laboratory must be capable of performing testing for the five classes of drugs (marijuana, cocaine, opiates, phencyclidine, and amphetamines) using the initial immunoassay and confirmatory GC/MS methods specified in these Guidelines.

(k) *Laboratory Facilities.* (1) Laboratory facilities shall comply with applicable provisions of any State licensure requirements.

(2) Laboratories certified in accordance with Subpart C of these Guidelines shall have the capability, at the same laboratory premises, of performing initial and confirmatory tests for each drug or metabolite for which service is offered.

(l) *Inspections.* The Secretary, any Federal agency utilizing the laboratory,

or any organization performing laboratory certification on behalf of the Secretary shall reserve the right to inspect the laboratory at any time.

Agency contracts with laboratories for drug testing, as well as contracts for collection site services, shall permit the agency to conduct unannounced inspections. In addition, prior to the award of a contract the agency shall carry out preaward inspections and evaluation of the procedural aspects of the laboratory's drug testing operation.

(m) *Documentation.* The drug testing laboratories shall maintain and make available for at least 2 years documentation of all aspects of the testing process. This 2-year period may be extended upon written notification by DHHS or by any Federal agency for which laboratory services are being provided. The required documentation shall include personnel files on all individuals authorized to have access to specimens; chain of custody documents; quality assurance/quality control records; procedure manuals; all test data (including calibration curves and any calculations used in determining test results); reports; performance records on performance testing; performance on certification inspections; and hard copies of computer-generated data. The laboratory shall be required to maintain documents for any specimen under legal challenge for an indefinite period.

(n) *Additional Requirements for Certified Laboratories.*—(1) *Procedure Manual.* Each laboratory shall have a procedure manual which includes the principles of each test, preparation of reagents, standards and controls, calibration procedures, derivation of results, linearity of methods, sensitivity of the methods, cutoff values, mechanisms for reporting results, controls, criteria for unacceptable specimens and results, remedial actions to be taken when the test systems are outside of acceptable limits, reagents and expiration dates, and references. Copies of all procedures and dates on which they are in effect shall be maintained as part of the manual.

(2) *Standards and Controls.* Laboratory standards shall be prepared with pure drug standards which are properly labeled as to content and concentration. The standards shall be labeled with the following dates: when received; when prepared or opened; when placed in services; and expiration date.

(3) *Instruments and Equipment.* (i) Volumetric pipettes and measuring devices shall be certified for accuracy or be checked by gravimetric, colorimetric, or other verification procedure. Automatic pipettes and dilutors shall be

checked for accuracy and reproducibility before being placed in service and checked periodically thereafter.

(ii) There shall be written procedures for instrument set-up and normal operation, a schedule for checking critical operating characteristics for all instruments, tolerance limits for acceptable function checks and instructions for major trouble shooting and repair. Records shall be available on preventive maintenance.

(4) *Remedial Actions.* There shall be written procedures for the actions to be taken when systems are out of acceptable limits or errors are detected. There shall be documentation that these procedures are followed and that all necessary corrective actions are taken. There shall also be in place systems to verify all stages of testing and reporting and documentation that these procedures are followed.

(5) *Personnel Available To Testify at Proceedings.* A laboratory shall have qualified personnel available to testify in an administrative or disciplinary proceeding against a Federal employee when that proceeding is based on positive urinalysis results reported by the laboratory.

2.5 Quality Assurance and Quality Control.

(a) *General.* Drug testing laboratories shall have a quality assurance program which encompasses all aspects of the testing process including but not limited to specimen acquisition, chain of custody, security and reporting of results, initial and confirmatory testing, and validation of analytical procedures. Quality assurance procedures shall be designed, implemented, and reviewed to monitor the conduct of each step of the process of testing for drugs.

(b) *Laboratory Quality Control Requirements for Initial Tests.* Each analytical run of specimens to be screened shall include:

- (1) Urine specimens certified to contain no drug;
- (2) Urine specimens fortified with known standards; and
- (3) Positive controls with the drug or metabolite at or near the threshold (cutoff).

In addition, with each batch of samples a sufficient number of standards shall be included to ensure and document the linearity of the assay method over time in the concentration area of the cutoff. After acceptable values are obtained for the known standards, those values will be used to calculate sample data. Implementation of procedures to ensure that carryover does not contaminate the

testing of an individual's specimen shall be documented. A minimum of 10 percent of all test samples shall be quality control specimens. Laboratory quality control samples, prepared from spiked urine samples of determined concentration shall be included in the run and should appear as normal samples to laboratory analysts. One percent of each run, with a minimum of at least one sample, shall be the laboratory's own quality control samples.

(c) Laboratory Quality Control Requirements for Confirmation Tests Each analytical run of specimens to be confirmed shall include:

- (1) Urine specimens certified to contain no drug;
- (2) Urine specimens fortified with known standards; and
- (3) Positive controls with the drug or metabolite at or near the threshold (cutoff).

The linearity and precision of the method shall be periodically documented. Implementation of procedures to ensure that carryover does not contaminate the testing of an individual's specimen shall also be documented.

(d) Agency Blind Performance Test Procedures. (1) Agencies shall purchase drug testing services only from laboratories certified by DHHS or a DHHS-Recognized certification program in accordance with these Guidelines. Laboratory participation is encouraged in other performance testing surveys by which the laboratory's performance is compared with peers and reference laboratories.

(2) During the initial 90-day period of any new drug testing program, each agency shall submit blind performance test specimens to each laboratory it contracts with in the amount of at least 50 percent of the total number of samples submitted (up to a maximum of 500 samples) and thereafter a minimum of 10 percent of all samples (to a maximum of 250) submitted per quarter.

(3) Approximately 80 percent of the blind performance test samples shall be blank (i.e., certified to contain no drug) and the remaining samples shall be positive for one or more drugs per sample in a distribution such that all the drugs to be tested are included in approximately equal frequencies of challenge. The positive samples shall be spiked only with those drugs for which the agency is testing.

(4) The Secretary shall investigate any unsatisfactory performance testing result and, based on this investigation, the laboratory shall take action to correct the cause of the unsatisfactory

performance test result. A record shall be made of the Secretary's investigative findings and the corrective action taken by the laboratory, and that record shall be dated and signed by the individuals responsible for the day-to-day management and operation of the drug testing laboratory. Then the Secretary shall send the document to the agency contracting officer as a report of the unsatisfactory performance testing incident. The Secretary shall ensure notification of the finding to all other Federal agencies for which the laboratory is engaged in urine drug testing and coordinate any necessary action.

(5) Should a false positive error occur on a blind performance test specimen and the error is determined to be an administrative error (clerical, sample mixup, etc.), the Secretary shall require the laboratory to take corrective action to minimize the occurrence of the particular error in the future; and, if there is reason to believe the error could have been systematic, the Secretary may also require review and reanalysis of previously run specimens.

(6) Should a false positive error occur on a blind performance test specimen and the error is determined to be a technical or methodological error, the laboratory shall submit all quality control data from the batch of specimens which included the false positive specimen. In addition, the laboratory shall retest all specimens analyzed positive for that drug or metabolite from the time of final resolution of the error back to the time of the last satisfactory performance test cycle. This retesting shall be documented by a statement signed by the individual responsible for day-to-day management of the laboratory's urine drug testing. The Secretary may require an on-site review of the laboratory which may be conducted unannounced during any hours of operations of the laboratory. The Secretary has the option of revoking (3.13) or suspending (3.14) the laboratory's certification or recommending that no further action be taken if the cause is one of less serious error in which corrective action has already been taken, thus reasonably assuring that the error will not occur again.

2.6 Interim Certification Procedures.

During the interim certification period as determined under paragraph (c), agencies shall ensure laboratory competence by one of the following methods:

- (a) Agencies may use agency or contract laboratories that have been

certified for urinalysis testing by the Department of Defense; or

(b) Agencies may develop interim self-certification procedures by establishing preaward inspections and performance testing plans approved by DHHS.

(c) The period during which these interim certification procedures will apply shall be determined by the Secretary. Upon noticed by the Secretary that these interim certification procedures are no longer available, all Federal agencies subject to these Guidelines shall only use laboratories that have been certified in accordance with Subpart C of these Guidelines and all laboratories approved for interim certification under paragraphs (a) and (b) of this section shall become certified in accordance with Subpart C within 120 days of the date of this notice.

2.7 Reporting and Review of Results.

(a) Medical Review Officer Shall Review Results. An essential part of the drug testing program is the final review of results. A positive test result does not automatically identify an employee/applicant as an illegal drug user. An individual with a detailed knowledge of possible alternate medical explanations is essential to the review of results. This review shall be performed by the Medical Review Officer prior to the transmission of results to agency administrative officials.

(b) Medical Review Officer—Qualifications and Responsibilities. The Medical Review Officer shall be a licensed physician with knowledge of substance abuse disorders and may be an agency or contract employee. The role of the Medical Review Officer is to review and interpret positive test results obtained through the agency's testing program. In carrying out this responsibility, the Medical Review Officer shall examine alternate medical explanations for any positive test result. This action could include conducting a medical interview with the individual, review of the individual's medical history, or review of any other relevant biomedical factors. The Medical Review Officer shall review all medical records made available by the tested individual when a confirmed positive test could have resulted from legally prescribed medication. The Medical Review Officer shall not, however, consider the results of urine samples that are not obtained or processed in accordance with these Guidelines.

(c) Positive Test Result. Prior to making a final decision to verify a positive test result, the Medical Review Officer shall give the individual an opportunity to discuss the test result

with him or her. Following verification of a positive test result, the Medical Review Officer shall refer the case to the agency Employee Assistance Program and to the management official empowered to recommend or take administrative action.

(d) *Verification for opiates; review for prescription medication.* Before the Medical Review Officer verifies a confirmed positive result for opiates, he or she shall determine that there is clinical evidence—in addition to the urine test—of illegal use of any opium, opiate, or opium derivative (e.g., morphine/codeine) listed in Schedule I or II of the Controlled Substances Act. (This requirement does not apply if the agency's GC/MS confirmation testing for opiates confirms the presence of 6-monoacetylmorphine.)

(e) *Reanalysis Authorized.* Should any question arise as to the accuracy or validity of a positive test result, only the Medical Review Officer is authorized to order a reanalysis of the original sample and such retests are authorized only at laboratories certified under these Guidelines.

(f) *Result Consistent with Legal Drug Use.* If the Medical Review Officer determines there is a legitimate medical explanation for the positive test result, he or she shall determine that the result is consistent with legal drug use and take no further action.

(g) *Result Scientifically Insufficient.* Additionally, the Medical Review Officer, based on review of inspection reports, quality control data, multiple samples, and other pertinent results, may determine that the result is scientifically insufficient for further action and declare the test specimen negative. In this situation the Medical Review Officer may request reanalysis of the original sample before making this decision. (The Medical Review Officer may request that reanalysis be performed by the same laboratory or, as provided in 2.7(e), that an aliquot of the original specimen be sent for reanalysis to an alternate laboratory which is certified in accordance with these Guidelines.) The laboratory shall assist in this review process as requested by the Medical Review Officer by making available the individual responsible for day-to-day management of the urine drug testing laboratory or other employee who is a forensic toxicologist or who has equivalent forensic experience in urine drug testing, to provide specific consultation as required by the agency. The Medical Review Officer shall report to the Secretary all negative findings based on scientific insufficiency but shall not include any

personal identifying information in such reports.

2.8 Protection of Employee Records.

Consistent with 5 U.S.C. 522a(m) and 48 CFR 24.101-24.104, all laboratory contracts shall require that the contractor comply with the Privacy Act, 5 U.S.C. 552a. In addition, laboratory contracts shall require compliance with the patient access and confidentiality provisions of section 503 of Pub. L. 100-71. The agency shall establish a Privacy Act System of Records or modify an existing system, or use any applicable Government-wide system of records to cover both the agency's and the laboratory's records of employee urinalysis results. The contract and the Privacy Act System shall specifically require that employee records be maintained and used with the highest regard for employee privacy.

2.9 Individual Access to Test and Laboratory Certification Results.

In accordance with section 503 of Pub. L. 100-71, any Federal employee who is the subject of a drug test shall, upon written request, have access to any records relating to his or her drug test and any records relating to the results of any relevant certification, review, or revocation-of-certification proceedings.

Subpart C—Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies

3.1 Introduction.

Urine drug testing is a critical component of efforts to combat drug abuse in our society. Many laboratories are familiar with good laboratory practices but may be unfamiliar with the special procedures required when drug test results are used in the employment context. Accordingly, the following are minimum standards to certify laboratories engaged in urine drug testing for Federal agencies. Certification, even at the highest level, does not guarantee accuracy of each result reported by a laboratory conducting urine drug testing for Federal agencies. Therefore, results from laboratories certified under these Guidelines must be interpreted with a complete understanding of the total collection, analysis, and reporting process before a final conclusion is made.

3.2 Goals and Objectives of Certification.

(a) *Uses of Urine Drug Testing.* Urine drug testing is an important tool to identify drug users in a variety of

settings. In the proper context, urine drug testing can be used to deter drug abuse in general. To be a useful tool, the testing procedure must be capable of detecting drugs or their metabolites at concentrations indicated in 2.4 (e) and (f).

(b) *Need to Set Standards; Inspections.* Reliable discrimination between the presence, or absence, of specific drugs or their metabolites is critical, not only to achieve the goals of the testing program but to protect the rights of the Federal employees being tested. Thus, standards have been set which laboratories engaged in Federal employee urine drug testing must meet in order to achieve maximum accuracy of test results. These laboratories will be evaluated by the Secretary or the Secretary's designee as defined in 1.2 in accordance with these Guidelines. The qualifying evaluation will involve three rounds of performance testing plus on-site inspection. Maintenance of certification requires participation in an every-other-month performance testing program plus periodic, on-site inspections. One inspection following successful completion of a performance testing regimen is required for initial certification. This must be followed by a second inspection within 3 months, after which biannual inspections will be required to maintain certification.

(c) *Urine Drug Testing Applies Analytical Forensic Toxicology.* The possible impact of a positive test result on an individual's livelihood or rights, together with the possibility of a legal challenge of the result, sets this type of test apart from most clinical laboratory testing. In fact, urine drug testing should be considered a special application of analytical forensic toxicology. That is, in addition to the application of appropriate analytical methodology, the specimen must be treated as evidence, and all aspects of the testing procedure must be documented and available for possible court testimony. Laboratories engaged in urine drug testing for Federal agencies will require the services and advice of a qualified forensic toxicologist, or individual with equivalent qualifications (both training and experience) to address the specific needs of the Federal drug testing program, including the demands of chain of custody of specimens, security, property documentation of all records, storage of positive specimens for later or independent testing, presentation of evidence in court, and expert witness testimony.

3.3 General Certification Requirements.

A laboratory must meet all the pertinent provisions of these Guidelines in order to qualify for certification under these standards.

3.4 Capability to Test for Five Classes of Drugs.

To be certified, a laboratory must be capable of testing for at least the following five classes of drugs: Marijuana, cocaine, opiates, amphetamines, and phencyclidine, using the initial immunoassay and quantitative confirmatory GC/MS methods specified in these Guidelines. The certification program will be limited to the five classes of drugs (2.1(a) (1) and (2)) and the methods (2.4 (e) and (f)) specified in these Guidelines. The laboratory will be surveyed and performance tested only for these methods and drugs. Certification of a laboratory indicates that any test result reported by the laboratory for the Federal Government meets the standards in these Guidelines for the five classes of using the methods specified. Certified laboratories must clearly inform non-Federal clients when procedures followed for those clients conform to the standards specified in these Guidelines.

3.5 Initial and Confirmatory Capability at Same Site.

Certified laboratories shall have the capability, at the same laboratory site, of performing both initial immunoassays and confirmatory GC/MS tests (2.4 (e) and (f)) for marijuana, cocaine, opiates, amphetamines, and phencyclidine and for any other drug or metabolite for which agency drug testing is authorized (2.1(a) (1) and (2)). All positive initial test results shall be confirmed prior to reporting them.

3.6 Personnel.

Laboratory personnel shall meet the requirements specified in 2.3 of these Guidelines. These Guidelines establish the exclusive standards for qualifying or certifying those laboratory personnel involved in urinalysis testing whose functions are prescribed by these Guidelines. A certification of a laboratory under these Guidelines shall be a determination that these qualification requirements have been met.

3.7 Quality Assurance and Quality Control.

Drug testing laboratories shall have a quality assurance program which encompasses all aspects of the testing process, including but not limited to

specimen acquisition, chain of custody, security and reporting of results, initial and confirmatory testing, and validation of analytical procedures. Quality control procedures shall be designed, implemented, and reviewed to monitor the conduct of each step of the process of testing for drugs as specified in 2.5 of these Guidelines.

3.8 Security and Chain of Custody.

Laboratories shall meet the security and chain of custody requirements provided in 2.4(a).

3.9 One-Year Storage for Confirmed Positives.

All confirmed positive specimens shall be retained in accordance with the provisions of 2.4(h) of these Guidelines.

3.10 Documentation.

The laboratory shall maintain and make available for at least 2 years documentation in accordance with the specifications in 2.4(m).

3.11 Reports.

The laboratory shall report test results in accordance with the specifications in 2.4(g).

3.12 Certification.

(a) *General.* The Secretary may certify any laboratory that meets the standards in these Guidelines to conduct urine drug testing. In addition, the Secretary may consider to be certified and laboratory that is certified by a DHHS-recognized certification program in accordance with these Guidelines.

(b) *Criteria.* In determining whether to certify a laboratory or to accept the certification of a DHHS-recognized certification program in accordance with these Guidelines, the Secretary shall consider the following criteria:

- (1) The adequacy of the laboratory facilities;
- (2) The expertise and experience of the laboratory personnel;
- (3) The excellence of the laboratory's quality assurance/quality control program;
- (4) The performance of the laboratory on any performance tests;
- (5) The laboratory's compliance with standards as reflected in any laboratory inspections; and
- (6) Any other factors affecting the reliability and accuracy of drug tests and reporting done by the laboratory.

3.13 Revocation.

(a) *General.* The Secretary shall revoke certification of any laboratory certified under these provisions or accept revocation by a DHHS-recognized certification program in

accordance with these Guidelines if the Secretary determines that revocation is necessary to ensure the full reliability and accuracy of drug tests and the accurate reporting of test results.

(b) *Factors to Consider.* The Secretary shall consider the following factors in determining whether revocation is necessary:

- (1) Unsatisfactory performance in analyzing and reporting the results of drug tests; for example, a false positive error in reporting the results of an employee's drug test;
- (2) Unsatisfactory participation in performance evaluations or laboratory inspections;
- (3) A material violation of a certification standard or a contract term or other condition imposed on the laboratory by a Federal agency using the laboratory's services;
- (4) Conviction for any criminal offense committed as an incident to operation of the laboratory; or
- (5) Any other cause which materially affects the ability of the laboratory to ensure the full reliability and accuracy of drug tests and the accurate reporting of results.

(c) *Period and Terms.* The period and terms of revocation shall be determined by the Secretary and shall depend upon the facts and circumstances of the revocation and the need to ensure accurate and reliable drug testing of Federal employees.

3.14 Suspension.

(a) *Criteria.* Whenever the Secretary has reason to believe that revocation may be required and that immediate action is necessary in order to protect the interests of the United States and its employees, the Secretary may immediately suspend a laboratory's certification to conduct urine drug testing for Federal agencies. The Secretary may also accept suspension of certification by a DHHS-recognized certification program in accordance with these Guidelines.

(b) *Period and Terms.* The period and terms of suspension shall be determined by the Secretary and shall depend upon the facts and circumstances of the suspension and the need to ensure accurate and reliable drug testing of Federal employees.

3.15 Notice; Opportunity for Review.

(a) *Written Notice.* When a laboratory is suspended or the Secretary seeks to revoke certification, the Secretary shall immediately serve the laboratory with written notice of the suspension or proposed revocation by personal service or registered or certified mail, return

receipt requested. This notice shall state the following:

(1) The reasons for the suspension or proposed revocation;

(2) The terms of the suspension or proposed revocation; and

(3) The period of suspension or proposed revocation.

(b) *Opportunity for Informal Review.* The written notice shall state that the laboratory will be afforded an opportunity for an informal review of the suspension or proposed revocation if it so requests in writing within 30 days of the date of mailing or service of the notice. The review shall be by a person or persons designated by the Secretary and shall be based on written submissions by the laboratory and the Department of Health and Human Services and, at the Secretary's discretion, may include an opportunity for an oral presentation. Formal rules of evidence and procedures applicable to proceedings in a court of law shall not apply. The decision of the reviewing official shall be final.

(c) *Effective Date.* A suspension shall be effective immediately. A proposed revocation shall be effective 30 days after written notice is given or, if review is requested, upon the reviewing official's decision to uphold the proposed revocation. If the reviewing official decides not to uphold the suspension or proposed revocation, the suspension shall terminate immediately and any proposed revocation shall not take effect.

(d) *DHHS-Recognized Certification Program.* The Secretary's responsibility under this section may be carried out by a DHHS-recognized certification program in accordance with these Guidelines.

3.16 *Recertification.*

Following the termination or expiration of any suspension or revocation, a laboratory may apply for recertification. Upon the submission of evidence satisfactory to the Secretary that the laboratory is in compliance with these Guidelines or any DHHS-recognized certification program in accordance with these Guidelines, and any other conditions imposed as part of the suspension or revocation, the Secretary may recertify the laboratory or accept the recertification of the laboratory by a DHHS-recognized certification program.

3.17 *Performance Test Requirement for Certification.*

(a) *An Initial and Continuing Requirement.* The performance testing program is a part of the initial evaluation of a laboratory seeking

certification (both performance testing and laboratory inspection are required) and of the continuing assessment of laboratory performance necessary to maintain this certification.

(b) *Three Initial Cycles Required.* Successful participation in three cycles of testing shall be required before a laboratory is eligible to be considered for inspection and certification. These initial three cycles (and any required for recertification) can be compressed into a 3-month period (one per month).

(c) *Six Challenges Per Year.* After certification, laboratories shall be challenged every other month with one set of at least 10 specimens a total of six cycles per year.

(d) *Laboratory Procedures Identical for Performance Test and Routine Employee Specimens.* All procedures associated with the handling and testing of the performance test specimens by the laboratory shall to the greatest extent possible be carried out in a manner identical to that applied to routine laboratory specimens, unless otherwise specified.

(e) *Blind Performance Test.* Any certified laboratory shall be subject to blind performance testing (see 2.5(d)). Performance on blind test specimens shall be at the same level as for the open or non-blind performance testing.

(f) *Reporting—Open Performance Test.* The laboratory shall report results of open performance tests to the certifying organization in the same manner as specified in 2.4(g)(2) for routine laboratory specimens.

3.18 *Performance Test Specimen Composition.*

(a) *Description of the Drugs.* Performance test specimens shall contain those drugs and metabolites which each certified laboratory must be prepared to assay in concentration ranges that allow detection of the analyte by commonly used immunoassay screening techniques. These levels are generally in the range of concentrations which might be expected in the urine of recent drug users. For some drug analytes, the specimen composition will consist of the parent drug as well as major metabolites. In some cases, more than one drug class may be included in one specimen container, but generally no more than two drugs will be present in any one specimen in order to imitate the type of specimen which a laboratory normally encounters. For any particular performance testing cycle, the actual composition of kits going to different laboratories will vary but, within any annual period, all laboratories

participating will have analyzed the same total set of specimens.

(b) *Concentrations.* Performance test specimens shall be spiked with the drug classes and their metabolites which are required for certifications: marijuana, cocaine, opiates, amphetamines, and phencyclidine, with concentration levels set at least 20 percent above the cutoff limit for either the initial assay or the confirmatory test, depending on which is to be evaluated. Some performance test specimens may be identified for GC/MS assay only. Blanks shall contain less than 2 ng/ml of any of the target drugs. These concentration and drug types may be changed periodically in response to factors such as changes in detection technology and patterns of drug use.

3.19 *Evaluation of Performance Testing.*

(a) *Initial Certification.* (1) An applicant laboratory shall not report any false positive result during performance testing for initial certification. Any false positive will automatically disqualify a laboratory from further consideration.

(2) An applicant laboratory shall maintain an overall grade level of 90 percent for the three cycles of performance testing required for initial certification, i.e., it must correctly identify and confirm 90 percent of the total drug challenges for each shipment. Any laboratory which achieves a score on any one cycle of the initial certification such that it can no longer achieve a total grade of 90 percent over the three cycles will be immediately disqualified from further consideration.

(3) An applicant laboratory shall obtain quantitative values for at least 80 percent of the total drug challenges which are ± 20 percent or ± 2 standard deviations of the calculated reference group mean (whichever is larger). Failure to achieve 80 percent will result in disqualification.

(4) An applicant laboratory shall not obtain any quantitative values that differ by more than 50 percent from the calculated reference group mean. Any quantitative values that differ by more than 50 percent will result in disqualification.

(5) For any individual drug, an applicant laboratory shall successfully detect and quantitate in accordance with paragraphs (a)(2), (a)(3), and (a)(4) of this section at least 50 percent of the total drug challenges. Failure to successfully quantitate at least 50 percent of the challenges for any individual drug will result in disqualification.

(b) *Ongoing Testing of Certified Laboratories.—(1) False Positives and Procedures for Dealing With Them.* No

false drug identifications are acceptable for any drugs for which a laboratory offers service. Under some circumstances a false positive test may result in suspension or revocation of certification. The most serious false positives are by drug class, such as reporting THC in a blank specimen or reporting cocaine in a specimen known to contain only opiates.

Misidentifications within a class (e.g., codeine for morphine) are also false positives which are unacceptable in an appropriately controlled laboratory, but they are clearly less serious errors than misidentification of a class. The following procedures shall be followed when dealing with a false positive:

(i) The agency detecting a false positive error shall immediately notify the laboratory and the Secretary of any such error.

(ii) The laboratory shall provide the Secretary with a written explanation of the reasons for the error within 5 working days. If required by paragraph (b)(1)(v) below, this explanation shall include the submission of all quality control data from the batch of specimens that included the false positive specimen.

(iii) The Secretary shall review the laboratory's explanation within 5 working days and decide what further action, if any, to take.

(iv) If the error is determined to be an administrative error (clerical, sample mixup, etc.), the Secretary may direct the laboratory to take corrective action to minimize the occurrence of the particular error in the future and, if there is reason to believe the error could have been systematic, may require the laboratory to review and reanalyze previously run specimens.

(v) If the error is determined to be technical or methodological error, the laboratory shall submit to the Secretary all quality control data from the batch of specimens which included the false positive specimen. In addition, the laboratory shall retest all specimens analyzed positive by the laboratory from the time of final resolution of the error back to the time of the last satisfactory performance test cycle. This retesting shall be documented by a statement signed by the individual responsible for the day-to-day management of the laboratory's urine drug testing. Depending on the type of error which caused the false positive, this retesting may be limited to one analyte or may include any drugs a laboratory certified under these Guidelines must be prepared to assay. The laboratory shall immediately notify the agency if any result on a retest sample must be corrected because the criteria for a positive are not satisfied. The Secretary may suspend or revoke the laboratory's

certification for all drugs or for only the drug or drug class in which the error occurred. However, if the case is one of a less serious error for which effective corrections have already been made, thus reasonably assuring that the error will not occur again, the Secretary may decide to take no further action.

(vi) During the time required to resolve the error, the laboratory shall remain certified but shall have a designation indicating that a false positive result is pending resolution. If the Secretary determines that the laboratory's certification must be suspended or revoked, the laboratory's official status will become "Suspended" or "Revoked" until the suspension or revocation is lifted or any recertification process is complete.

(2) *Requirement to Identify and Confirm 90 Percent of Total Drug Challenges.* In order to remain certified, laboratories must successfully complete six cycles of performance testing per year. Failure of a certified laboratory to maintain a grade of 90 percent on any required performance test cycle, i.e., to identify 90 percent of the total drug challenges and to correctly confirm 90 percent of the total drug challenges, may result in suspension or revocation of certification.

(3) *Requirement to Quantitate 80 Percent of Total Drug Challenges at ± 20 Percent or ± 2 standard deviations.* Quantitative values obtained by a certified laboratory for at least 80 percent of the total drug challenges must be ± 20 percent or ± 2 standard deviations of the calculated reference group mean (whichever is larger).

(4) *Requirement to Quantitate within 50 Percent of Calculated Reference Group Mean.* No quantitative values obtained by a certified laboratory may differ by more than 50 percent from the calculated reference group mean.

(5) *Requirement to Successfully Detect and Quantitate 50 Percent of the Total Drug Challenges for Any Individual Drug.* For any individual drug, a certified laboratory must successfully detect and quantitate in accordance with paragraphs (b)(2), (b)(3), and (b)(4) of this section at least 50 percent of the total drug challenges.

(6) *Procedures When Requirements in Paragraphs (b)(2)-(b)(5) of this Section Are Not Met.* If a certified laboratory fails to maintain a grade of 90 percent per test cycle after initial certification as required by paragraph (b)(2) of this section or if it fails to successfully quantitate results as required by paragraphs (b)(3), (b)(4), or (b)(5) of this section, the laboratory shall be immediately informed that its performance fell under the 90 percent level or that it failed to successfully quantitate test results and how it failed

to successfully quantitate. The laboratory shall be allowed 5 working days in which to provide any explanation for its unsuccessful performance, including administrative error or methodological error, and evidence that the source of the poor performance has been corrected. The Secretary may revoke or suspend the laboratory's certification or take no further action, depending on the seriousness of the errors and whether there is evidence that the source of the poor performance has been corrected and that current performance meets the requirements for a certified laboratory under these Guidelines. The Secretary may require that additional performance tests be carried out to determine whether the source of the poor performance has been removed. If the Secretary determines to suspend or revoke the laboratory's certification, the laboratory's official status will become "Suspended" or "Revoked" until the suspension or revocation is lifted or until any recertification process is complete.

(c) *80 Percent of Participating Laboratories Must Detect Drug.* A laboratory's performance shall be evaluated for all samples for which drugs were spiked at concentrations above the specified performance test level unless the overall response from participating laboratories indicates that less than 80 percent of them were able to detect a drug.

(d) *Participation Required.* Failure to participate in a performance test or to participate satisfactorily may result in suspension or revocation of certification.

3.20 Inspections.

Prior to laboratory certification under these Guidelines and at least twice a year after certification, a team of three qualified inspectors, at least two of whom have been trained as laboratory inspectors, shall conduct an on-site inspection of laboratory premises. Inspections shall document the overall quality of the laboratory setting for the purposes of certification to conduct urine drug testing. Inspection reports may also contain recommendations to the laboratory to correct deficiencies noted during the inspection.

3.21 Results of Inadequate Performance.

Failure of a laboratory to comply with any aspect of these Guidelines may lead to revocation or suspension of certification as provided in 3.13 and 3.14 of these Guidelines.

APPENDIX B

FBI/DEA Policy Memorandum dated May 7, 1986



U.S. Department of Justice

Federal Bureau of Investigation

Washington, D.C. 20535

**DRUG DETERRENCE POLICY STATEMENT
FEDERAL BUREAU OF INVESTIGATION
DRUG ENFORCEMENT ADMINISTRATION**

The following policy statement sets forth the details of the Federal Bureau of Investigation (FBI) and Drug Enforcement Administration (DEA) Drug Deterrence Program.

FBI and DEA employees (both Agent and support) are prohibited from the illegal use of drugs or narcotics, the violation of any Federal drug law, or the abuse of any drugs or narcotics at any time. The penalty for violation of this prohibition will be administrative action up to and including dismissal.

(1) Prior to or immediately after coming onboard, all employees of the FBI and DEA will be required to have urine tests performed for drugs of abuse. (Enclosed is a list of drugs that will be included in the screening program and their detection levels.)


(2) All FBI and DEA Special Agents and all DEA Diversion Investigators and DEA chemists will be required to submit to urinalysis testing for drugs of abuse prior to the end of their probationary period.

(3) The FBI and DEA will require any employee to submit to a urinalysis testing for drugs of abuse where a reasonable suspicion exists that an employee may be abusing controlled substances. An employee will only be required to submit to a urinalysis testing when two supervisory personnel (one of whom must be at least at the Assistant Director (AD), Assistant Administrator or Special Agent in Charge (SAC) level, or in their absence a Deputy AD, Deputy Assistant Administrator, Assistant SAC (ASAC) or Country Attache) concur that a reasonable basis exists to suspect that the employee has illegally used a controlled substance. Failure to comply will be considered insubordination and will result in administrative action up to and including dismissal.

(4) A program for a computer generated random selection process for aperiodic drug testing of all FBI and DEA employees is under development.


(5) Upon approval of the aforementioned policy all FBI and DEA employees and prospective applicants will be notified concerning the drug deterrence policy.

Approval:




John C. Lawn
Administrator

Date:




May 6, 1986

Approval:



William H. Webster
Director

Date:



May 7, 1986

Enclosure

DRUGS TO BE SCREENED

<u>DRUG</u>	<u>CATEGORY</u>	<u>INITIAL SCREEN</u>	<u>CONFIRMATION METHOD</u>	<u>DETECTION LIMIT*</u>	<u>DETECTION PERIOD****</u>
Amphetamines Amphetamines Metamphetamine	Stimulant	EMIT	GC-MS	1.5ug/ml	Medium Medium
Barbiturates Amobarbital Butobarbital Pentobarbital Phenobarbital Secobarbital	Sedative	EMIT	GC-MS	200ng/ml	Medium Medium/Long Medium Long Medium
Benzodiazepines Chlordiazepoxide (Librium) Diazepam (Valium)	Sedative	EMIT	GC-MS	300ng/ml	Medium/Long Long
Cocaine Benzoyllecgonine	Stimulant	EMIT	GC-MS	300ng/ml	Short
Cannabinoids (THC, Marijuana)	Euphoric	EMIT	GC-MS	20ng/ml or 100ng/ml***	Varied/Long
Opiates** Codeine Hydromorphone (Dilaudid) Morphine (for Heroin)	Analgesic	EMIT	GC-MS	300ng/ml	Medium Short/Medium Medium
Methaqualone (Quaalude)	Sedative	EMIT	GC-MS	750ng/ml	Long
Phencyclidine (PCP, Angel Dust)	Anesthetic/ Hallucinogen	EMIT	GC-MS	25ng/ml	Varied
Methadone (metabolite)					

ug/ml = micrograms per milliliter; ng/ml = nanograms per milliliter; %w/v = percent weight/volume

*The detection limit given for a class of drugs, e.g., 200ng/ml for Barbiturates, pertains to the specific drug contained in the system calibrator

**Interpretation of positive morphine and/or codeine results is complex and may require consultation with the laboratory in cases where a prescription for a codeine containing medication is involved.

***For cannabinoids, customer should specify desired detection level.

****Detection period definition: short = 12 to 48 hrs.; medium = 2 to 4 days; long = up to 30 days; varied = wide ranging category depending primarily on drug use history (casual use detected 2-7 days; chronic use detected one month or longer).

APPENDIX C

Notification Memorandum to All FBI Employees
dated June 3, 1986



Federal Bureau of Investigation

Washington, D.C. 20535

June 3, 1986

MEMORANDUM TO ALL EMPLOYEES

RE: FBI/DEA DRUG DETERRENCE PROGRAM

As we are all aware, drug abuse is the Nation's Number One crime problem. The FBI and DEA, as the investigative agencies responsible for enforcing Federal narcotics violations, can be in the forefront in meeting this challenge head-on. I am sure each of you will agree that we have consistently shown the American public that we are responsible for our actions and that we are steadfast in our commitment to eliminate the drug problem. We have set high standards for our employees, and your commitment to meeting these standards has earned us respect and admiration throughout the law enforcement community.

The FBI and DEA have formed a working group to consider ways in which we can reaffirm this commitment and communicate it in a positive way so that it will capture the attention and support of others. Together we have initiated a Drug Deterrence Program, to include implementation of urinalysis for all new employees. A similar future program is being developed for on-board employees. Special care has been taken to preserve the privacy and rights of all employees, and I know each of you will provide the support and cooperation necessary to ensure that the program is met with a positive attitude.

The following policy statement sets forth the details of the FBI and DEA Drug Deterrence Program:

- (1) Prior to or immediately after coming on board, all employees of the FBI and DEA will be required to have urine tests performed for drugs of abuse.
- (2) All FBI and DEA Special Agents, DEA Diversion Investigators and DEA chemists will be required to submit to a urinalysis for drugs of abuse prior to the end of their probationary period.

6-3-86

MEMORANDUM TO ALL EMPLOYEES 4-86

(3) The FBI and DEA will require any employee to submit to a urinalysis for drugs of abuse where a reasonable suspicion exists that an employee may be abusing controlled substances. An employee will only be required to submit to a urinalysis when two supervisory personnel (one of whom must be at least at the Assistant Director (AD), Assistant Administrator or Special Agent in Charge (SAC) level, or in their absence a Deputy AD, Deputy Assistant Administrator, Assistant SAC (ASAC) or Country Attache) concur that a reasonable basis exists to suspect that the employee has illegally used a controlled substance. Failure to comply will be considered insubordination and will result in administrative action up to and including dismissal.

(4) A program for a computer generated random selection process for aperiodic drug testing of all FBI and DEA employees is under development.

As this policy is implemented, you will be advised of additional details. I trust you appreciate the importance of this policy and will give it the support necessary to make implementation as smooth as possible.

William H. Webster
Director

APPENDIX D

Collection and Chain of Custody Form (FD-716)



Memorandum

To :

Date

From :

Account No. # 250001

Subject : FBI Drug Deterrence Program

- Applicant
 Random
 Follow Up
 Probationary
 Reasonable Suspicion
 Voluntary

Report of Urine Specimen Collected for Drug Screening

Social Security Number:

Date

and time

Temp

Color

Collecting Official: *(print name)*

Medications being taken:

Chain of Custody

Purpose of Change of Custody	Released By: Signature Print Name	Received By: Signature Print Name	Date
Specimen Shipment	<i>(Collector's Signature)</i>	Federal Express	

For Laboratory Use Only:

Laboratory Accession Number _____

Receiving Codes: _____

Remarks: _____

* Field Office fill in shaded areas.

Original (Include with Specimen)

APPENDIX E

FBI Drug Deterrence Program Acknowledgment Form

Federal Bureau Of Investigation
Drug Deterrence Program Acknowledgment

Drug abuse is the Nation's number one crime problem. The Federal Bureau of Investigation and the Drug Enforcement Administration, as the investigative agencies responsible for enforcing Federal narcotics violations, must be in the forefront in meeting this challenge head-on. We have set high standards for our employees, and our commitment to meeting these standards has earned us respect and admiration throughout the law enforcement community. Drug abuse, therefore, by employees of the FBI and DEA is intolerable and totally unacceptable. It is, therefore, imperative that the FBI and DEA should take a leadership role by demonstrating the absolute integrity of these agencies and their work forces in the effort to stem the flow and abuse of controlled substances.

I understand the FBI's intolerance of substance abuse and that I will be screened by urinalysis testing for the presence of marijuana and other controlled substance prior to or shortly after reporting for training and at other times as directed throughout my FBI career. I further understand that a single detection of drug abuse or refusal to submit to this testing may result in administrative action up to and including dismissal from the FBI.

I have read and understand all provisions of the FBI Drug Deterrence Program.

- I have not taken any medications (DRUGS) during the past month.
- I have taken the following medications during the past month:

NAME (PRINT)

SIGNATURE

DATE

APPENDIX F

Description of Select Support Positions

1. Librarian, FBI Academy, Quantico, Virginia:

Available to conduct research for FBI Agents in support of all investigations, including foreign counterintelligence investigations, requiring access to or knowledge of classified information, and has excess to the details of the FBI Academy's course curriculum which contains sensitive information.

2. General maintenance employees, FBI Headquarters and Field Offices:

The maintenance of building facilities under ownership or control of the FBI requires unimpeded access to all locations and equipment. Employees thereby obtain knowledge of sensitive equipment and have the capability of gaining access to classified information. For instance, trash collection and disposal must be performed by employees with the highest degree of trust as they are responsible for segregating and shredding all classified and otherwise sensitive documents.

3. Automobile mechanics:

The FBI's fleet of vehicles must be maintained in a condition suitable for dangerous high speed driving. There is no margin for mechanical error due to a mechanic's mistake caused by the effects of illegal drug use. In addition, a mechanic's access to FBI vehicles gives him or her access to sensitive electronic equipment and when it is being used and for what purpose. A mechanic has knowledge of the license plates maintained on FBI vehicles and not registered publicly with the Department of Motor Vehicles. This information would be of value to those with interests adverse to the FBI and illegal drug use would greatly enhance an auto mechanics exposure to blackmail.

4. Warehouse and supply clerks:

These employees have knowledge of and access to sensitive equipment used by the FBI, which also affords them exposure to being compromised for illegal drug use.

5. Computer programmers and other computer related positions:

The FBI maintains a number of sensitive computer programs and uses sensitive computer equipment which allow knowledgeable employees access to a wealth of confidential and other sensitive information.

6. Laboratory scientists and technicians:

The scientific analysis of evidence which will be relied upon by the Federal and State judicial proceedings and other scientific work in support of the FBI's mission, requires careful and accurate job performance by employees unencumbered by illegal drug use. Some of these employees are exposed to illegal drugs

during the course of their investigations and would be in a position to misappropriate such drugs to support an illegal drug habit. Other employees are assigned to emergency disaster teams and are on-call 24 hours a day to be prepared to respond to worldwide disasters; they must be alert and drug free at all hours, on or off duty.

7. Fingerprint examiners:

These employees have access to a voluminous amount of personal information, such as the identity of individuals wanted by the FBI and other law enforcement agencies. This knowledge would afford such employees the ability to compromise their official positions if they were to be threatened with exposure and consequent loss of their employment and livelihood because of illegal drug use.